IP Review

This publication includes IP covered under the following statements.

https://creativecommons.org/licenses/by-nc-sa/4.0/
Show Usage
- Evidence Based Medicine on FHIR Implementation Guide Code System : ADAS_Cog11_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version , Add_on_Amlodipine_at_6_weeks ... Show 375 more
- ResearchStudy Classifier Code System : CTIS_2024_516402_32_00_FHIR_Transform , ResearchStudyClassifier , ResearchStudySite , StudyDesign and StudyRegistryRecord
https://creativecommons.org/licenses/by-sa/4.0/
Show Usage
- Recommendation Justification Code System : All_cause_mortality_from_MAGICapp_313876 , All_cause_mortality_from_MAGICapp_313956 ... Show 25 more
ISO maintains the copyright on the country codes, and controls its use carefully. For further details see the ISO 3166 web page: https://www.iso.org/iso-3166-country-codes.html
Show Usage
- ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code : Year_2018_Norwegian_Cohort_Study
Most of the information on the CDC and ATSDR websites is not subject to copyright, is in the public domain, and may be freely used or reproduced without obtaining copyright permission.For information and exceptions regarding use of CDC material please see https://www.cdc.gov/other/agencymaterials.html .
Show Usage
- CDC Race and Ethnicity : ConceptualCohortDefinition_BMI_27_5_32_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery , ConceptualCohortDefinition_BMI_32_5_37_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery and ConceptualCohortDefinition_BMI_37_5_kg_m2_in_Asian_Americans
Please see https://www.meddra.org/legal-mentions . For information about special licensing, see https://www.meddra.org/subscription/special-licences
Show Usage
- Medical Dictionary for Regulatory Activities : CTIS_2024_516402_32_00_FHIR_Transform
SEVCO has an open license: https://creativecommons.org/licenses/by-sa/4.0/ Copyright holder is Scientific Knowledge Accelerator Foundation.
Show Usage
- Scientific Evidence Code System (SEVCO) : ADAS_Cog11_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version , Age_with_comparator ... Show 273 more
The UCUM codes, UCUM table (regardless of format), and UCUM Specification are copyright 1999-2009, Regenstrief Institute, Inc. and the Unified Codes for Units of Measures (UCUM) Organization. All rights reserved. https://ucum.org/trac/wiki/TermsOfUse
Show Usage
- Unified Code for Units of Measure (UCUM) : ADAS_Cog11_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version , ActivityDefinition/375159 ... Show 73 more
This material contains content from LOINC . LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license . LOINC® is a registered United States trademark of Regenstrief Institute, Inc.
Show Usage
- LOINC : Composition/256358 , Composition/343018 ... Show 32 more
This material contains content that is copyright of SNOMED International. Implementers of these specifications must have the appropriate SNOMED CT Affiliate license - for more information contact https://www.snomed.org/get-snomed or info@snomed.org .
Show Usage
- SNOMED Clinical Terms® (SNOMED CT®): ActivityDefinition/375159 , Add_on_Amlodipine_at_6_weeks ... Show 53 more
This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html
Show Usage
Using RxNorm codes of type SAB=RXNORM as this specification describes does not require a UMLS license. Access to the full set of RxNorm definitions, and/or additional use of other RxNorm structures and information requires a UMLS license. The use of RxNorm in this specification is pursuant to HL7's status as a licensee of the NLM UMLS. HL7's license does not convey the right to use RxNorm to any users of this specification; implementers must acquire a license to use RxNorm in their own right.
Show Usage
- RxNorm : ActivityDefinition/375159 , ActivityDefinition/375181 , High_Blood_Pressure_Medication_Value_Set and IV_remdesivir_200_mg_then_100_mg_day_for_9_days

IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot3 based on FHIR 6.0.0-ballot3. Generated 2026-03-27 Links: Table of Contents | QA Report | Version History | CC0 | Propose a change ( src )

hl7.fhir.us.hai: Healthcare Associated Infection Implementation Guide ®© HL7 | CC0 ( src )

15.803 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )

: SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )

A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus [Database Entry: FHIR ResearchStudy Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267223. Revised 2025-12-11. Available at: https://fevir.net/resources/ResearchStudy/267223. Computable resource at: https://fevir.net/resources/ResearchStudy/267223#json. ( src )

Adults with type 2 diabetes and CVD and CKD [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236947. Revised 2025-10-07. Available at: https://fevir.net/resources/Group/236947. Computable resource at: https://fevir.net/resources/Group/236947#json. ( src )

Adults with type 2 diabetes and established CVD (but no CKD) [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236533. Revised 2026-01-29. Available at: https://fevir.net/resources/Group/236533. Computable resource at: https://fevir.net/resources/Group/236533#json. ( src )

Artifact Author: Computable Publishing®: CTIS-to-FEvIR Converter: ( src )

Artifact Author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: ( src )

Artifact Author: Computable Publishing®: MAGIC-to-FEvIR Converter: ( src )

Artifact Author: Computable Publishing®: [System]-to-FEvIR Converter: ( src )

Change in Mean Diastolic Blood Pressure (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367884. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367884. Computable resource at: https://fevir.net/resources/EvidenceVariable/367884#json. ( src )

Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367943. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367943. Computable resource at: https://fevir.net/resources/Evidence/367943#json. ( src )

Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367908. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367908. Computable resource at: https://fevir.net/resources/Evidence/367908#json. ( src )

Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367907. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367907. Computable resource at: https://fevir.net/resources/Evidence/367907#json. ( src )

Change in Mean Systolic Blood Pressure (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367882. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367882. Computable resource at: https://fevir.net/resources/EvidenceVariable/367882#json. ( src )

Change in Mean Systolic Blood Pressure (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367891. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367891. Computable resource at: https://fevir.net/resources/EvidenceVariable/367891#json. ( src )

Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367941. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367941. Computable resource at: https://fevir.net/resources/Evidence/367941#json. ( src )

Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367904. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367904. Computable resource at: https://fevir.net/resources/Evidence/367904#json. ( src )

Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367903. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367903. Computable resource at: https://fevir.net/resources/Evidence/367903#json. ( src )

Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367951. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367951. Computable resource at: https://fevir.net/resources/Evidence/367951#json. ( src )

Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367926. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367926. Computable resource at: https://fevir.net/resources/Evidence/367926#json. ( src )

Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367925. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367925. Computable resource at: https://fevir.net/resources/Evidence/367925#json. ( src )

Citation: SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )

Codes for use with the Classifier drop-down menu for FEvIR(R): Recommendation Justification Builder. ( src )

ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236776. Revised 2026-01-29. Available at: https://fevir.net/resources/Group/236776. Computable resource at: https://fevir.net/resources/Group/236776#json. ( src )

ComparatorDefinition: Standard care [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236530. Revised 2026-01-29. Available at: https://fevir.net/resources/Group/236530. Computable resource at: https://fevir.net/resources/Group/236530#json. ( src )

Computable Publishing® augments digital publishing with machine-interpretable forms. Computable Publishing® offers publishers of any type (commercial, nonprofit, academic, government) the ability to extend their published works with computable (machine-interpretable) forms of expression, and users of any type support in using computable data to enhance, improve and achieve desired outcomes. ( src )

Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )

Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Executable app], version 4.9.1. Contributors: Computable Publishing LLC [Author]. In: Fast Evidence Interoperability Resources (FEvIR) Platform. Published June 04, 2021. Revised October 09, 2023. Accessed November 25, 2023. Available at: https://fevir.net/ctgovconvert. ( src )

Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter converts ClinicalTrials.gov JSON to FEvIR Resources in FHIR® JSON. • Enter an NCT Identifier (NCTID) and click Submit. • FHIR Resources will be created for all Protocol and Results Section Data in the ClinicalTrials.gov record. • For related articles listed in MEDLINE, the Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter automates use of the Computable Publishing®: MEDLINE-to-FEvIR Converter. ( src )

Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter is one of the many Converter tools on the FEvIR Platform. • Converter Tools transform data between known structured forms and the FHIR standard form. • The FEvIR Platform provides access to an array of tools which enable creating and viewing scientific knowledge in standard-based, machine-interpretable units called Resources. ( src )

Defines the content expected to be rendered in all representations of the artifact. The (c) symbol should NOT be included in this string. It is expected to be added by software when rendering the notation. Full details about licensing, restrictions, warrantees, etc. goes in the more general 'copyright' element. ( src )

Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU) [Database Entry: FHIR ResearchStudy Resource]. Contributors: Computable Publishing®: CTIS-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 346485. Revised 2026-01-26. Available at: https://fevir.net/resources/ResearchStudy/346485. Computable resource at: https://fevir.net/resources/ResearchStudy/346485#json. ( src )

Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension [Database Entry: FHIR ResearchStudy Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367879. Revised 2025-09-13. Available at: https://fevir.net/resources/ResearchStudy/367879. Computable resource at: https://fevir.net/resources/ResearchStudy/367879#json. ( src )

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions ( src )

GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236948. Revised 2026-01-29. Available at: https://fevir.net/resources/Group/236948. Computable resource at: https://fevir.net/resources/Group/236948#json. ( src )

GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236535. Revised 2026-01-29. Available at: https://fevir.net/resources/Group/236535. Computable resource at: https://fevir.net/resources/Group/236535#json. ( src )

GLUCAGEN® and GLUCAGEN® Hypokit 1 mg (glucagon) Product Monograph. Mississauga, Ontario: Novo Nordisk Canada Inc.; 2014. http://www.paladin-labs.com/our_products/PM_GlucaGen_EN.pdf. Accessed 26 September 2015. ( src )

GroupAssignment: GLP-1 RA vs. Standard care [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236536. Revised 2025-10-07. Available at: https://fevir.net/resources/EvidenceVariable/236536. Computable resource at: https://fevir.net/resources/EvidenceVariable/236536#json. ( src )

GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236950. Revised 2025-10-07. Available at: https://fevir.net/resources/EvidenceVariable/236950. Computable resource at: https://fevir.net/resources/EvidenceVariable/236950#json. ( src )

Health-related Quality of Life (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367890. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367890. Computable resource at: https://fevir.net/resources/EvidenceVariable/367890#json. ( src )

Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370509. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/370509. Computable resource at: https://fevir.net/resources/EvidenceVariable/370509#json. ( src )

Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367924. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367924. Computable resource at: https://fevir.net/resources/Evidence/367924#json. ( src )

Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367923. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367923. Computable resource at: https://fevir.net/resources/Evidence/367923#json. ( src )

Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370508. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/370508. Computable resource at: https://fevir.net/resources/EvidenceVariable/370508#json. ( src )

Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367922. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367922. Computable resource at: https://fevir.net/resources/Evidence/367922#json. ( src )

Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367921. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367921. Computable resource at: https://fevir.net/resources/Evidence/367921#json. ( src )

Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367949. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367949. Computable resource at: https://fevir.net/resources/Evidence/367949#json. ( src )

Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367950. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367950. Computable resource at: https://fevir.net/resources/Evidence/367950#json. ( src )

InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236532. Revised 2026-01-29. Available at: https://fevir.net/resources/Group/236532. Computable resource at: https://fevir.net/resources/Group/236532#json. ( src )

InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236769. Revised 2026-01-29. Available at: https://fevir.net/resources/Group/236769. Computable resource at: https://fevir.net/resources/Group/236769#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236955. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236955. Computable resource at: https://fevir.net/resources/Evidence/236955#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236541. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236541. Computable resource at: https://fevir.net/resources/Evidence/236541#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236988. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236988. Computable resource at: https://fevir.net/resources/Evidence/236988#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236568. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236568. Computable resource at: https://fevir.net/resources/Evidence/236568#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236958. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236958. Computable resource at: https://fevir.net/resources/Evidence/236958#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236544. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236544. Computable resource at: https://fevir.net/resources/Evidence/236544#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236973. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236973. Computable resource at: https://fevir.net/resources/Evidence/236973#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236967. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236967. Computable resource at: https://fevir.net/resources/Evidence/236967#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236553. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236553. Computable resource at: https://fevir.net/resources/Evidence/236553#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236979. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236979. Computable resource at: https://fevir.net/resources/Evidence/236979#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236985. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236985. Computable resource at: https://fevir.net/resources/Evidence/236985#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236565. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236565. Computable resource at: https://fevir.net/resources/Evidence/236565#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236970. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236970. Computable resource at: https://fevir.net/resources/Evidence/236970#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236556. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236556. Computable resource at: https://fevir.net/resources/Evidence/236556#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236961. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236961. Computable resource at: https://fevir.net/resources/Evidence/236961#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236547. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236547. Computable resource at: https://fevir.net/resources/Evidence/236547#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236964. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236964. Computable resource at: https://fevir.net/resources/Evidence/236964#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236550. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236550. Computable resource at: https://fevir.net/resources/Evidence/236550#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236976. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236976. Computable resource at: https://fevir.net/resources/Evidence/236976#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236559. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236559. Computable resource at: https://fevir.net/resources/Evidence/236559#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236982. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236982. Computable resource at: https://fevir.net/resources/Evidence/236982#json. ( src )

MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236562. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236562. Computable resource at: https://fevir.net/resources/Evidence/236562#json. ( src )

MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236540. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236540. Computable resource at: https://fevir.net/resources/Evidence/236540#json. ( src )

MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236954. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236954. Computable resource at: https://fevir.net/resources/Evidence/236954#json. ( src )

MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236567. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236567. Computable resource at: https://fevir.net/resources/Evidence/236567#json. ( src )

MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236987. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236987. Computable resource at: https://fevir.net/resources/Evidence/236987#json. ( src )

MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236543. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236543. Computable resource at: https://fevir.net/resources/Evidence/236543#json. ( src )

MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236957. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236957. Computable resource at: https://fevir.net/resources/Evidence/236957#json. ( src )

MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236972. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236972. Computable resource at: https://fevir.net/resources/Evidence/236972#json. ( src )

MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236552. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236552. Computable resource at: https://fevir.net/resources/Evidence/236552#json. ( src )

MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236966. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236966. Computable resource at: https://fevir.net/resources/Evidence/236966#json. ( src )

MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236978. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236978. Computable resource at: https://fevir.net/resources/Evidence/236978#json. ( src )

MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236564. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236564. Computable resource at: https://fevir.net/resources/Evidence/236564#json. ( src )

MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236984. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236984. Computable resource at: https://fevir.net/resources/Evidence/236984#json. ( src )

MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236555. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236555. Computable resource at: https://fevir.net/resources/Evidence/236555#json. ( src )

MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236969. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236969. Computable resource at: https://fevir.net/resources/Evidence/236969#json. ( src )

MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236546. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236546. Computable resource at: https://fevir.net/resources/Evidence/236546#json. ( src )

MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236960. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236960. Computable resource at: https://fevir.net/resources/Evidence/236960#json. ( src )

MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236549. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236549. Computable resource at: https://fevir.net/resources/Evidence/236549#json. ( src )

MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236963. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236963. Computable resource at: https://fevir.net/resources/Evidence/236963#json. ( src )

MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236558. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236558. Computable resource at: https://fevir.net/resources/Evidence/236558#json. ( src )

MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236975. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236975. Computable resource at: https://fevir.net/resources/Evidence/236975#json. ( src )

MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236561. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236561. Computable resource at: https://fevir.net/resources/Evidence/236561#json. ( src )

MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236981. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236981. Computable resource at: https://fevir.net/resources/Evidence/236981#json. ( src )

MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293872. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293872. Computable resource at: https://fevir.net/resources/Evidence/293872#json. ( src )

MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293980. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293980. Computable resource at: https://fevir.net/resources/Evidence/293980#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293881. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293881. Computable resource at: https://fevir.net/resources/Evidence/293881#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293991. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293991. Computable resource at: https://fevir.net/resources/Evidence/293991#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293873. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293873. Computable resource at: https://fevir.net/resources/Evidence/293873#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293981. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293981. Computable resource at: https://fevir.net/resources/Evidence/293981#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293986. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293986. Computable resource at: https://fevir.net/resources/Evidence/293986#json. ( src )

MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293876. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293876. Computable resource at: https://fevir.net/resources/Evidence/293876#json. ( src )

MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293984. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293984. Computable resource at: https://fevir.net/resources/Evidence/293984#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293988. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293988. Computable resource at: https://fevir.net/resources/Evidence/293988#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293880. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293880. Computable resource at: https://fevir.net/resources/Evidence/293880#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293990. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293990. Computable resource at: https://fevir.net/resources/Evidence/293990#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293877. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293877. Computable resource at: https://fevir.net/resources/Evidence/293877#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293985. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293985. Computable resource at: https://fevir.net/resources/Evidence/293985#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293874. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293874. Computable resource at: https://fevir.net/resources/Evidence/293874#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293982. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293982. Computable resource at: https://fevir.net/resources/Evidence/293982#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293875. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293875. Computable resource at: https://fevir.net/resources/Evidence/293875#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293983. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293983. Computable resource at: https://fevir.net/resources/Evidence/293983#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293878. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293878. Computable resource at: https://fevir.net/resources/Evidence/293878#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293987. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293987. Computable resource at: https://fevir.net/resources/Evidence/293987#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293879. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293879. Computable resource at: https://fevir.net/resources/Evidence/293879#json. ( src )

MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293989. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293989. Computable resource at: https://fevir.net/resources/Evidence/293989#json. ( src )

Mean Change in Blood Urea Nitrogen (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367901. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367901. Computable resource at: https://fevir.net/resources/EvidenceVariable/367901#json. ( src )

Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367957. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367957. Computable resource at: https://fevir.net/resources/Evidence/367957#json. ( src )

Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367938. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367938. Computable resource at: https://fevir.net/resources/Evidence/367938#json. ( src )

Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367937. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367937. Computable resource at: https://fevir.net/resources/Evidence/367937#json. ( src )

Mean Change in Serum Creatinine (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367902. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367902. Computable resource at: https://fevir.net/resources/EvidenceVariable/367902#json. ( src )

Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367958. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367958. Computable resource at: https://fevir.net/resources/Evidence/367958#json. ( src )

Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367940. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367940. Computable resource at: https://fevir.net/resources/Evidence/367940#json. ( src )

Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367939. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367939. Computable resource at: https://fevir.net/resources/Evidence/367939#json. ( src )

Mean Change in Serum Potassium (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367899. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367899. Computable resource at: https://fevir.net/resources/EvidenceVariable/367899#json. ( src )

Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367955. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367955. Computable resource at: https://fevir.net/resources/Evidence/367955#json. ( src )

Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367934. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367934. Computable resource at: https://fevir.net/resources/Evidence/367934#json. ( src )

Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367933. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367933. Computable resource at: https://fevir.net/resources/Evidence/367933#json. ( src )

Mean Change in Serum Sodium (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367900. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367900. Computable resource at: https://fevir.net/resources/EvidenceVariable/367900#json. ( src )

Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367956. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367956. Computable resource at: https://fevir.net/resources/Evidence/367956#json. ( src )

Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367936. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367936. Computable resource at: https://fevir.net/resources/Evidence/367936#json. ( src )

Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367935. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367935. Computable resource at: https://fevir.net/resources/Evidence/367935#json. ( src )

Mean Diastolic Blood Pressure (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367885. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367885. Computable resource at: https://fevir.net/resources/EvidenceVariable/367885#json. ( src )

Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367944. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367944. Computable resource at: https://fevir.net/resources/Evidence/367944#json. ( src )

Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367910. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367910. Computable resource at: https://fevir.net/resources/Evidence/367910#json. ( src )

Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367909. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367909. Computable resource at: https://fevir.net/resources/Evidence/367909#json. ( src )

Mean Systolic Blood Pressure (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367883. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367883. Computable resource at: https://fevir.net/resources/EvidenceVariable/367883#json. ( src )

Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367942. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367942. Computable resource at: https://fevir.net/resources/Evidence/367942#json. ( src )

Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367906. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367906. Computable resource at: https://fevir.net/resources/Evidence/367906#json. ( src )

Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367905. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367905. Computable resource at: https://fevir.net/resources/Evidence/367905#json. ( src )

Medication Adherence (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367889. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367889. Computable resource at: https://fevir.net/resources/EvidenceVariable/367889#json. ( src )

Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367948. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367948. Computable resource at: https://fevir.net/resources/Evidence/367948#json. ( src )

Medication Adherence at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367920. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367920. Computable resource at: https://fevir.net/resources/Evidence/367920#json. ( src )

Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367919. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367919. Computable resource at: https://fevir.net/resources/Evidence/367919#json. ( src )

Methods Adult symptomatic patients with mild COVID-19 were recruited between May and August 2020 from King Abdulaziz University Hospital in Jeddah, Saudi Arabia. They were randomly assigned to receive supplementation with oral capsules of NSO (MARNYS® Cuminmar 500 mg twice daily for 10 days) plus standard of care or standard of care medications alone. The primary endpoint was the proportion of patients recovered (free of symptoms for 3 days) within 14 days after randomization. This trial was registered with clinicaltrials.gov, NCT04401202. ( src )

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate Cancer (Version 1.2016). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. ( src )

NCT03421379 Eligibility Criteria [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267225. Revised 2025-12-11. Available at: https://fevir.net/resources/Group/267225. Computable resource at: https://fevir.net/resources/Group/267225#json. ( src )

NCT03640312 Eligibility Criteria [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367881. Revised 2025-08-18. Available at: https://fevir.net/resources/Group/367881. Computable resource at: https://fevir.net/resources/Group/367881#json. ( src )

Number of Patients Requiring Step up Treatment (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367887. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367887. Computable resource at: https://fevir.net/resources/EvidenceVariable/367887#json. ( src )

Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367946. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367946. Computable resource at: https://fevir.net/resources/Evidence/367946#json. ( src )

Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367916. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367916. Computable resource at: https://fevir.net/resources/Evidence/367916#json. ( src )

Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367915. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367915. Computable resource at: https://fevir.net/resources/Evidence/367915#json. ( src )

PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267228. Revised 2025-12-11. Available at: https://fevir.net/resources/EvidenceVariable/267228. Computable resource at: https://fevir.net/resources/EvidenceVariable/267228#json. ( src )

PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267237. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267237. Computable resource at: https://fevir.net/resources/Evidence/267237#json. ( src )

PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267236. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267236. Computable resource at: https://fevir.net/resources/Evidence/267236#json. ( src )

PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267230. Revised 2025-12-11. Available at: https://fevir.net/resources/EvidenceVariable/267230. Computable resource at: https://fevir.net/resources/EvidenceVariable/267230#json. ( src )

PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267241. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267241. Computable resource at: https://fevir.net/resources/Evidence/267241#json. ( src )

PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267240. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267240. Computable resource at: https://fevir.net/resources/Evidence/267240#json. ( src )

PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267231. Revised 2025-12-11. Available at: https://fevir.net/resources/EvidenceVariable/267231. Computable resource at: https://fevir.net/resources/EvidenceVariable/267231#json. ( src )

PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267243. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267243. Computable resource at: https://fevir.net/resources/Evidence/267243#json. ( src )

PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267242. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267242. Computable resource at: https://fevir.net/resources/Evidence/267242#json. ( src )

Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267226. Revised 2025-12-11. Available at: https://fevir.net/resources/EvidenceVariable/267226. Computable resource at: https://fevir.net/resources/EvidenceVariable/267226#json. ( src )

Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267244. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267244. Computable resource at: https://fevir.net/resources/Evidence/267244#json. ( src )

Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267233. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267233. Computable resource at: https://fevir.net/resources/Evidence/267233#json. ( src )

Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267232. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267232. Computable resource at: https://fevir.net/resources/Evidence/267232#json. ( src )

Percentage of Participants With Potentially Related Adverse Events (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367897. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367897. Computable resource at: https://fevir.net/resources/EvidenceVariable/367897#json. ( src )

Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367953. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367953. Computable resource at: https://fevir.net/resources/Evidence/367953#json. ( src )

Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367930. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367930. Computable resource at: https://fevir.net/resources/Evidence/367930#json. ( src )

Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367929. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367929. Computable resource at: https://fevir.net/resources/Evidence/367929#json. ( src )

Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367896. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367896. Computable resource at: https://fevir.net/resources/EvidenceVariable/367896#json. ( src )

Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367952. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367952. Computable resource at: https://fevir.net/resources/Evidence/367952#json. ( src )

Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367928. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367928. Computable resource at: https://fevir.net/resources/Evidence/367928#json. ( src )

Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367927. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367927. Computable resource at: https://fevir.net/resources/Evidence/367927#json. ( src )

Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267227. Revised 2025-12-11. Available at: https://fevir.net/resources/EvidenceVariable/267227. Computable resource at: https://fevir.net/resources/EvidenceVariable/267227#json. ( src )

Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267235. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267235. Computable resource at: https://fevir.net/resources/Evidence/267235#json. ( src )

Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267234. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267234. Computable resource at: https://fevir.net/resources/Evidence/267234#json. ( src )

Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267229. Revised 2025-12-11. Available at: https://fevir.net/resources/EvidenceVariable/267229. Computable resource at: https://fevir.net/resources/EvidenceVariable/267229#json. ( src )

Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267239. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267239. Computable resource at: https://fevir.net/resources/Evidence/267239#json. ( src )

Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267238. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267238. Computable resource at: https://fevir.net/resources/Evidence/267238#json. ( src )

Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367888. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367888. Computable resource at: https://fevir.net/resources/EvidenceVariable/367888#json. ( src )

Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367947. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367947. Computable resource at: https://fevir.net/resources/Evidence/367947#json. ( src )

Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367918. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367918. Computable resource at: https://fevir.net/resources/Evidence/367918#json. ( src )

Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367917. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367917. Computable resource at: https://fevir.net/resources/Evidence/367917#json. ( src )

Proportion of Patients With Hypertension Control (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367886. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367886. Computable resource at: https://fevir.net/resources/EvidenceVariable/367886#json. ( src )

Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370507. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/370507. Computable resource at: https://fevir.net/resources/EvidenceVariable/370507#json. ( src )

Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367914. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367914. Computable resource at: https://fevir.net/resources/Evidence/367914#json. ( src )

Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367913. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367913. Computable resource at: https://fevir.net/resources/Evidence/367913#json. ( src )

Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370506. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/370506. Computable resource at: https://fevir.net/resources/EvidenceVariable/370506#json. ( src )

Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367912. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367912. Computable resource at: https://fevir.net/resources/Evidence/367912#json. ( src )

Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367911. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367911. Computable resource at: https://fevir.net/resources/Evidence/367911#json. ( src )

Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367945. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367945. Computable resource at: https://fevir.net/resources/Evidence/367945#json. ( src )

Rate of Adverse Events of Special Interest (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367898. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367898. Computable resource at: https://fevir.net/resources/EvidenceVariable/367898#json. ( src )

Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367954. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367954. Computable resource at: https://fevir.net/resources/Evidence/367954#json. ( src )

Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367932. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367932. Computable resource at: https://fevir.net/resources/Evidence/367932#json. ( src )

Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367931. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367931. Computable resource at: https://fevir.net/resources/Evidence/367931#json. ( src )

Results Section for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267224. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/267224. Computable resource at: https://fevir.net/resources/Composition/267224#json. ( src )

Results Section for NCT03640312 [Database Entry: FHIR Composition Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367880. Revised 2025-08-18. Available at: https://fevir.net/resources/Composition/367880. Computable resource at: https://fevir.net/resources/Composition/367880. ( src )

SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236949. Revised 2026-01-29. Available at: https://fevir.net/resources/Group/236949. Computable resource at: https://fevir.net/resources/Group/236949#json. ( src )

SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )

SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot3 ( src )

SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - JSON Representation - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot3 ( src )

SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - TTL Representation - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot3 ( src )

SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - XML Representation - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot3 ( src )

Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236534. Revised 2026-01-29. Available at: https://fevir.net/resources/Group/236534. Computable resource at: https://fevir.net/resources/Group/236534#json. ( src )

The (c) symbol should NOT be included in this string. It will be added by software when rendering the notation. Full details about licensing, restrictions, warrantees, etc. goes in the more general 'copyright' element. ( src )

The purpose of this research was to describe and interpret the positive body image experiences of women actively engaged in pole fitness. A total of seven women between the ages of 20 and 36 years participated in semistructured one-on-one interviews and follow-up interviews. Participant observation was also used to generate data. Data were analyzed using an interpretative phenomenological analysis approach, and the positive body image experiences of women are represented by five themes: (a) observation and exposure fostering body acceptance, (b) performance promoting self-confidence, (c) personal growth and sexual expression, (d) unconditional community support creates comfort, and (e) body appreciation through physical skill development. Findings suggest that women engaging in pole fitness may experience positive body image, and the words of participants provide insight into the components of pole fitness that may foster positive body image. Pole fitness may provide a unique exercise context whereby women can develop and maintain positive body image. ( src )

The short copyright declaration (e.g. (c) '2015+ xyz organization' should be sent in the copyrightLabel element. ( src )

This material contains content from LOINC. LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license. LOINC® is a registered United States trademark of Regenstrief Institute, Inc. Show Usage * LOINC: Composition/256358, Composition/343018... Show 32 more, ConceptualCohortDefinition_At_least_2_risk_factors_for_stroke, ConceptualCohortDefinition_BMI_27_5_32_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_30_34_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_32_5_37_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_35_39_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_35_and_at_least_1_obesity_related_comorbidity, ConceptualCohortDefinition_BMI_37_5_kg_m2_in_Asian_Americans, ConceptualCohortDefinition_BMI_criteria_for_ADA_surgery_recommendation, ConceptualCohortDefinition_Oxygen_saturation_below_96_on_Boots_Finger_Pulse_Oximeter, ConceptualCohortDefinition_Oxygen_saturation_below_96_on_Boots_Finger_Pulse_Oximeter_with_Ranges, ConceptualCohortDefinition_Proxy_criteria_for_surgical_candidates, ConceptualCohortDefinition_Severe_obesity, EGFR_45_59, Ethnic_Group, Group/267506, Group/279346, Group/279347, Group/282882, Group/297750, Hypertension_Control_at_12_weeks, M11Report, OutcomeDefinition_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control, OutcomeDefinition_HbA1c_at_12_months, OutcomeDefinition_HbA1c_at_24_months, OutcomeDefinition_HbA1c_at_36_months, OutcomeDefinition_HbA1c_at_60_months, OutcomeDefinition_HbA1c_at_6_months, QUARTET_Eligibility_Criteria, StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study, StudyEligibilityCriteria_Eligibility_Criteria_for_DIBASY_Trial, StudyEligibilityCriteria_Obese_patients_18_years_old and Type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis ( src )

This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html Show Usage * StatisticAttribute Estimate Type: ComparativeEvidence_Bariatric_Surgery_effect_for_ADA_triple_outcome_at_5_years_Diabetes_Surgery_Study, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2014... Show 34 more, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Cummings_2016, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ding_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Dixon_2008, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Halperin_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Liang_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2012_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2015_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Parikh_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2012_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Wentworth_2014, MeanDiffA1c2016metaAnalysis, NCT03421379_primaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_0_OutcomeAnalysis_11_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_1_OutcomeAnalysis_12_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_2_OutcomeAnalysis_13_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_3_OutcomeAnalysis_14_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_4_OutcomeAnalysis_15_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_5_OutcomeAnalysis_16_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_6_OutcomeAnalysis_17_BetweenGroupAnalysis_OG000_OG001, NCT03640312_primaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_0_OutcomeAnalysis_1_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_1_OutcomeAnalysis_2_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_2_OutcomeAnalysis_3_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_3_OutcomeAnalysis_4_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_4_OutcomeAnalysis_5_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_5_OutcomeAnalysis_6_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_6_OutcomeAnalysis_7_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_7_OutcomeAnalysis_8_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_7_OutcomeAnalysis_9_BetweenGroupAnalysis_OG000_OG001 and NCT03640312_secondaryOutcomeMeasure_8_OutcomeAnalysis_10_BetweenGroupAnalysis_OG000_OG001 * StatisticCertaintyRating: ArtifactAssessment/179693, ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study... Show 5 more, ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study and EvidenceAssessment * EvidenceDirectness: Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19 and Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY * LibraryType: Library/179606, Library/179618... Show 4 more, Library/179632, SearchResults, SystematicReviewExcludedStudies and SystematicReviewIncludedStudies * List Empty Reasons: Composition/178426, Composition/179465... Show 8 more, Composition/179466, Composition/179467, Composition/179699, Composition/236538, Composition/236951, Composition/256358, Composition/292951 and Composition/372776 * Organization type: Computable_Publishing_LLC * PlanDefinitionType: PlanDefinition/179468, PlanDefinition/179554 and RecommendationPlan * ResearchStudyObjectiveType: CTIS_2024_516402_32_00_FHIR_Transform, NCT03421379_FHIR_Transform and NCT03640312_FHIR_Transform * Research Study Party Role: CTIS_2024_516402_32_00_FHIR_Transform and NCT03421379_FHIR_Transform * ResearchStudyPhase: NCT03421379_FHIR_Transform, NCT03421379_FHIR_Transform_M11_IGBJ and NCT03640312_FHIR_Transform * ResearchStudyPrimaryPurposeType: NCT03421379_FHIR_Transform, NCT03421379_FHIR_Transform_M11_IGBJ and NCT03640312_FHIR_Transform * Research Study Status: CTIS_2024_516402_32_00_FHIR_Transform and NCT03421379_FHIR_Transform * StatisticStatisticType: ADAS_Cog11_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, CIBIC_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version... Show 16 more, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Cummings_2016, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ding_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Dixon_2008, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Halperin_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Liang_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2012_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2015_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Parikh_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2012_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Wentworth_2014 and MeanDiffA1c2016metaAnalysis * StatisticSynthesisType: AllCauseMortality2022metaAnalysis, AllCauseMortalityControlGroup2022metaAnalysis... Show 35 more, ComparativeEvidence_Bariatric_Surgery_effect_for_ADA_triple_outcome_at_5_years_Diabetes_Surgery_Study, ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Cummings_2016, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ding_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Dixon_2008, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Halperin_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Liang_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2012_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2015_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Parikh_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2012_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Wentworth_2014, ComparatorOnlyEvidence_Additional_GI_surgical_procedure_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Myocardial_infarction_or_stroke_without_bariatric_surgery_Control_Group_in_Swedish_Obese_Subjects_SOS_study, ComparatorOnlyEvidence_New_onset_depression_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Remission_of_diabetes_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Treatment_with_opioids_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, Death_or_Major_Traumatic_Injury_on_Impact_comparing_intervention_vs_comparator, Example_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, InterventionOnlyEvidence_Additional_GI_surgical_procedure_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_New_onset_depression_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Remission_of_diabetes_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Treatment_with_opioids_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, MeanDiffA1c2016metaAnalysis, NMA_Diabetes and SingleStudyEvidence * UsageContextType: Citation/112, Citation/5296... Show 5 more, Citation/7636, Citation/7638, Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19, NCT03421379_Results and NCT03640312_Results * identifierType: ADAS_Cog11_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, ActivityDefinition/375159... Show 700 more, ActivityDefinition/375181, Add_on_Amlodipine_at_6_weeks, Adults_with_type_2_diabetes, Adults_with_type_2_diabetes_with_moderate_CV_risk, Adverse_event_free_and_hypertension_control_at_12_weeks, Age, Age_with_comparator, Age_with_intervention, Aircraft_Type_with_comparator, Aircraft_Type_with_intervention, AllCauseMortality2022metaAnalysis, AllCauseMortalityControlGroup2022metaAnalysis, All_cause_mortality313876, All_cause_mortality313956, All_cause_mortality_Comparator_Evidence_from_MAGICapp_313876, All_cause_mortality_Comparator_Evidence_from_MAGICapp_313956, All_cause_mortality_Intervention_Evidence_from_MAGICapp_313876, All_cause_mortality_Intervention_Evidence_from_MAGICapp_313956, All_cause_mortality_from_MAGICapp_313876, All_cause_mortality_from_MAGICapp_313956, Altitude, Altitude_comparing_intervention_vs_comparator, Altitude_for_enrolled_group, Altitude_for_screened_group, Altitude_with_comparator, Altitude_with_intervention, An_example_of_OutcomeDefinition_Profile_which_is_a_conceptual_group_used_to_provided_a_definition_for_an_EvidenceVariable, Analyte_type_of_the_sample, ArtifactAssessment/104064, ArtifactAssessment/104192, ArtifactAssessment/104193, ArtifactAssessment/104194, ArtifactAssessment/104195, ArtifactAssessment/104196, ArtifactAssessment/171898, ArtifactAssessment/179448, ArtifactAssessment/179469, ArtifactAssessment/179515, ArtifactAssessment/179692, ArtifactAssessment/179693, ArtifactAssessment/179694, ArtifactAssessment/179698, ArtifactAssessment/179700, ArtifactAssessment/181452, ArtifactAssessment/307449, ArtifactAssessment/385882, ArtifactAssessment/423309, ArtifactAssessment/423310, ArtifactAssessment/423312, ArtifactAssessment/423313, ArtifactAssessment/423314, ArtifactAssessment/423315, Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_16, Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_17, Bariatric_Surgery_RYGB_VSG_LAGB_BPD, BaselineMeasureEvidence_Age_in_2018_Norwegian_Cohort_Medical_Group, BaselineMeasureEvidence_Age_in_2018_Norwegian_Cohort_Surgical_Group, BaselineMeasureEvidence_BMI_in_2018_Norwegian_Cohort_Medical_Group, BaselineMeasureEvidence_BMI_in_2018_Norwegian_Cohort_Surgical_Group, Birthdate, Body_site_where_sample_was_collected, Body_weight109570, Body_weight109588, Body_weight_Comparator_Evidence_from_MAGICapp_109570, Body_weight_Comparator_Evidence_from_MAGICapp_109588, Body_weight_Intervention_Evidence_from_MAGICapp_109570, Body_weight_Intervention_Evidence_from_MAGICapp_109588, Body_weight_from_MAGICapp_109570, Body_weight_from_MAGICapp_109588, CIBIC_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, COVID_19PneumoniaHospitalizedAdult, CTIS2024_516402_32_00_Eligibility_Criteria, CTIS2024_516402_32_00_Primary_Outcome_1, CTIS2024_516402_32_00_Secondary_Outcome_1, CTIS2024_516402_32_00_Secondary_Outcome_2, CTIS2024_516402_32_00_Secondary_Outcome_3, CTIS2024_516402_32_00_Secondary_Outcome_4, CTIS2024_516402_32_00_Secondary_Outcome_5, CTIS2024_516402_32_00_Secondary_Outcome_6, CTIS2024_516402_32_00_Secondary_Outcome_7, CTIS2024_516402_32_00_Secondary_Outcome_8, CTIS_2024_516402_32_00_FHIR_Transform, Cardiovascular_mortality313877, Cardiovascular_mortality313957, Cardiovascular_mortality_Comparator_Evidence_from_MAGICapp_313877, Cardiovascular_mortality_Comparator_Evidence_from_MAGICapp_313957, Cardiovascular_mortality_Intervention_Evidence_from_MAGICapp_313877, Cardiovascular_mortality_Intervention_Evidence_from_MAGICapp_313957, Cardiovascular_mortality_from_MAGICapp_313877, Cardiovascular_mortality_from_MAGICapp_313957, Case_id, Change_in_Mean_Diastolic_Blood_Pressure_NCT03640312, Change_in_Mean_Systolic_Blood_Pressure_NCT03640312, Citation/104116, Citation/112, Citation/121719, Citation/139859, Citation/139860, Citation/153881, Citation/179558, Citation/179559, Citation/179560, Citation/179561, Citation/179594, Citation/179595, Citation/179596, Citation/179597, Citation/179598, Citation/179599, Citation/179600, Citation/179601, Citation/179602, Citation/179603, Citation/179604, Citation/179605, Citation/179613, Citation/179615, Citation/179616, Citation/179617, Citation/179621, Citation/179622, Citation/179623, Citation/179624, Citation/179625, Citation/179626, Citation/179627, Citation/179628, Citation/179629, Citation/179630, Citation/179631, Citation/179637, Citation/247416, Citation/264329, Citation/267246, Citation/267247, Citation/267496, Citation/267497, Citation/267498, Citation/267499, Citation/267500, Citation/267501, Citation/29812, Citation/306957, Citation/32137, Citation/33089, Citation/33399, Citation/33400, Citation/367878, Citation/385938, Citation/5296, Citation/58, Citation/7636, Citation/7638, CodeSystemRecommendationJustification, ComparativeBaselineMeasureEvidence_Age_in_2018_Norwegian_Cohort_Surgical_Group_vs_Medical_Group, ComparativeBaselineMeasureEvidence_BMI_in_2018_Norwegian_Cohort_Surgical_Group_vs_Medical_Group, ComparativeEvidenceReportSubject_Association_of_Bariatric_Surgery_vs_Medical_Obesity_Treatment_With_Long_term_Medical_Complications_and_Obesity_Related_Comorbidities_2018_Norwegian_Cohort, ComparativeEvidence_Bariatric_Surgery_effect_for_ADA_triple_outcome_at_5_years_Diabetes_Surgery_Study, ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Cummings_2016, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ding_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Dixon_2008, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Halperin_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Liang_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2012_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2015_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Parikh_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2012_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Wentworth_2014, ComparativeParticipantFlowEvidence_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial, ComparatorDefinition_Obese_patients_18_years_old_without_bariatric_surgery, ComparatorGroup_JAMA_2018_Norwegian_cohort_study_Control_cohort, ComparatorOnlyEvidence_Additional_GI_surgical_procedure_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Myocardial_infarction_or_stroke_without_bariatric_surgery_Control_Group_in_Swedish_Obese_Subjects_SOS_study, ComparatorOnlyEvidence_New_onset_depression_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Remission_of_diabetes_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Treatment_with_opioids_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, Composition/104215, Composition/104383, Composition/178426, Composition/179465, Composition/179466, Composition/179467, Composition/179699, Composition/236537, Composition/236538, Composition/236951, Composition/256358, Composition/292951, Composition/307245, Composition/307248, Composition/312172, Composition/312203, Composition/318262, Composition/342828, Composition/343007, Composition/343018, Composition/370502, Composition/370503, Composition/370504, Composition/370505, Composition/370510, Composition/370512, Composition/372776, Composition/375280, Composition/397488, Composition/399871, Composition/399872, Composition/399873, Composition/399874, Computable_Publishing_LLC, ConceptualCohortDefinition_At_least_2_risk_factors_for_stroke, ConceptualCohortDefinition_BMI_27_5_32_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_30_34_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_32_5_37_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_35_39_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_35_and_at_least_1_obesity_related_comorbidity, ConceptualCohortDefinition_BMI_37_5_kg_m2_in_Asian_Americans, ConceptualCohortDefinition_BMI_criteria_for_ADA_surgery_recommendation, ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years, ConceptualCohortDefinition_Cardiovascular_event, ConceptualCohortDefinition_Heart_failure_based_on_Phenotypes, ConceptualCohortDefinition_Lower_BMI_criteria_for_ADA_surgery_consideration, ConceptualCohortDefinition_Nonfatal_myocardial_infarction, ConceptualCohortDefinition_Nonfatal_stroke, ConceptualCohortDefinition_Oxygen_saturation_below_96_on_Boots_Finger_Pulse_Oximeter, ConceptualCohortDefinition_Oxygen_saturation_below_96_on_Boots_Finger_Pulse_Oximeter_with_Ranges, ConceptualCohortDefinition_Proxy_criteria_for_surgical_candidates, ConceptualCohortDefinition_Severe_obesity, ConceptualComparatorDefinition_NOT_Bariatric_Surgery_RYGB_VSG_LAGB_BPD, ConceptualComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis, ConceptualExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin, Condition_code, Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19, Cs_ebm_ig, DIO_Mortality, Death_or_Major_Traumatic_Injury_30_days_after_Impact_comparing_intervention_vs_comparator, Death_or_Major_Traumatic_Injury_30_days_after_Impact_with_comparator, Death_or_Major_Traumatic_Injury_30_days_after_Impact_with_intervention, Death_or_Major_Traumatic_Injury_on_Impact_comparing_intervention_vs_comparator, Declined_randomization_in_PARACHUTE_Study, Deemed_unsuitable_by_investigator_in_PARACHUTE_Trial, DeviceDefinition/179899, Diabetic_ketoacidosis313962, Diabetic_ketoacidosis_Comparator_Evidence_from_MAGICapp_313962, Diabetic_ketoacidosis_Intervention_Evidence_from_MAGICapp_313962, Diabetic_ketoacidosis_from_MAGICapp_313962, Diastolic_blood_pressure_at_12_weeks, DichotomousIntendedOutcome_Additional_gastrointestinal_surgical_procedure, DichotomousIntendedOutcome_Death_or_Major_Traumatic_Injury_within_30_days, DichotomousIntendedOutcome_New_onset_depression, DichotomousIntendedOutcome_Nonfatal_myocardial_infarction_or_stroke, DichotomousIntendedOutcome_Remission_of_diabetes, DichotomousIntendedOutcome_Treatment_with_opioids, DocumentReference/367832, DocumentReference/367833, EGFR_45_59, End_stage_kidney_disease313880, End_stage_kidney_disease313960, End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313880, End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313960, End_stage_kidney_disease_Intervention_Evidence_from_MAGICapp_313880, End_stage_kidney_disease_Intervention_Evidence_from_MAGICapp_313960, End_stage_kidney_disease_from_MAGICapp_313880, End_stage_kidney_disease_from_MAGICapp_313960, Ethnic_Group, Ethnic_Group_with_comparator, Ethnic_Group_with_intervention, EvidenceReportSectionCode_Value_Set, EvidenceReportSubject_Clinical_Outcomes_for_Effects_of_Bariatric_Surgery, EvidenceVariableHandlingExtensionValueSet, Evidence_for_Results_for_Add_on_Amlodipine_at_6_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Add_on_Amlodipine_at_6_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Add_on_Amlodipine_at_6_weeks_in_QUARTET_USA_Trial_Quadpill_group, Evidence_for_Results_for_Adverse_event_free_and_hypertension_control_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Adverse_event_free_and_hypertension_control_at_12_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Adverse_event_free_and_hypertension_control_at_12_weeks_in_QUARTET_USA_Trial_Quadpill_group, Evidence_for_Results_for_Diastolic_blood_pressure_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Diastolic_blood_pressure_at_12_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Diastolic_blood_pressure_at_12_weeks_in_QUARTET_USA_Trial_Quadpill_group, Evidence_for_Results_for_Hypertension_Control_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Hypertension_Control_at_12_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Hypertension_Control_at_12_weeks_in_QUARTET_USA_Trial_Quadpill_group, Evidence_for_Results_for_Medication_Adherence_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Medication_Adherence_at_12_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Medication_Adherence_at_12_weeks_in_QUARTET_USA_Trial_Quadpill_group, Evidence_for_Results_for_Systolic_blood_pressure_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Systolic_blood_pressure_at_12_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Systolic_blood_pressure_at_12_weeks_in_QUARTET_USA_Trial_Quadpill_group, Example_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, Example_Variable_Definition_for_EBMonFHIR_IG, Example_variable_definition_for_the_EBMonFHIR_IG, Excluded_from_PARACHUTE_Study, ExposureGroup_JAMA_2018_Norwegian_cohort_study_Surgery_cohort, ExposureVariable_Age_as_continuous_variable, ExposureVariable_Body_Mass_Index_as_continuous_variable, Family_History_of_Parachute_Use, Family_History_of_Parachute_Use_with_comparator, Family_History_of_Parachute_Use_with_intervention, Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY, Frequent_Flier, Frequent_Flier_with_comparator, Frequent_Flier_with_intervention, GLU_J, Gender, Genital_infection313964, Genital_infection_Comparator_Evidence_from_MAGICapp_313964, Genital_infection_Intervention_Evidence_from_MAGICapp_313964, Genital_infection_from_MAGICapp_313964, Glucagon_Like_Peptide_1_GLP_1_receptor_agonists85390_I_85789, Glucagon_Like_Peptide_1_GLP_1_receptor_agonists85394_C_85798, Group/236534, Group/236535, Group/236948, Group/236949, Group/264323, Group/264328, Group/265092, Group/265093, Group/267506, Group/270503, Group/279340, Group/279346, Group/279347, Group/282882, Group/282891, Group/282899, Group/292955, Group/297486, Group/297487, Group/297488, Group/297489, Group/297750, Group/306655, Group/306657, Group/306658, Group/306659, Group/306660, Group/307440, Group/33395, Group/370701, Group/370702, Group/372797, Group/375175, Group/375182, Group/375279, GroupAssignment_Bariatric_Surgery_vs_no_bariatric_surgery, GroupAssignment_ExposureDefinition_Bariatric_Surgery_RYGB_VSG_LAGB_BPD_vs_ComparatorDefinition_NOT_Bariatric_Surgery_RYGB_VSG_LAGB_BPD, GroupAssignment_ExposureGroup_JAMA_2018_Norwegian_cohort_study_Surgery_cohort_vs_ComparatorGroup_JAMA_2018_Norwegian_cohort_study_Control_cohort, GroupAssignment_GLP_1_RA_vs_Standard_care, GroupAssignment_Jumping_from_aircraft_with_parachute_vs_Jumping_from_aircraft_with_empty_backpack, GroupAssignment_Non_Participants_vs_Enrolled_Participants, GroupAssignment_Quadpill_vs_Candesartan, GroupAssignment_Roux_en_Y_gastric_bypass_or_Biliopancreatic_Diversion_vs_medical_treatment, GroupAssignment_Roux_en_Y_gastric_bypass_surgery_vs_Lifestyle_intensive_medical_management_intervention_alone, GroupAssignment_Roux_en_Y_gastric_bypass_vs_medical_treatment, GroupAssignment_SGLT2_inhibitors_vs_GLP_1_RA, GroupAssignment_high_dose_xanomeline_vs_low_dose_xanomeline_vs_placebo, Health_Survey_Score_Mental_Health_Subscore, Health_Survey_Score_Mental_Health_Subscore_comparing_intervention_vs_comparator, Health_Survey_Score_Mental_Health_Subscore_with_comparator, Health_Survey_Score_Mental_Health_Subscore_with_intervention, Health_Survey_Score_Physical_Health_Subscore, Health_Survey_Score_Physical_Health_Subscore_comparing_intervention_vs_comparator, Health_Survey_Score_Physical_Health_Subscore_with_comparator, Health_Survey_Score_Physical_Health_Subscore_with_intervention, Health_Survey_Score_Total, Health_Survey_Score_Total_comparing_intervention_vs_comparator, Health_Survey_Score_Total_with_comparator, Health_Survey_Score_Total_with_intervention, Health_related_Quality_of_Life_NCT03640312, Health_related_Quality_of_Life_at_12_weeks_Change_in_Mental_Health_T_score_PROMIS_at_NCT03640312, Health_related_Quality_of_Life_at_12_weeks_Change_in_Physical_Health_T_score_PROMIS_at_NCT03640312, Health_related_quality_of_life109569, Health_related_quality_of_life109587, Health_related_quality_of_life_Comparator_Evidence_from_MAGICapp_109569, Health_related_quality_of_life_Comparator_Evidence_from_MAGICapp_109587, Health_related_quality_of_life_Intervention_Evidence_from_MAGICapp_109569, Health_related_quality_of_life_Intervention_Evidence_from_MAGICapp_109587, Health_related_quality_of_life_from_MAGICapp_109569, Health_related_quality_of_life_from_MAGICapp_109587, Heart_failure313881, Heart_failure313961, Heart_failure_Comparator_Evidence_from_MAGICapp_313881, Heart_failure_Comparator_Evidence_from_MAGICapp_313961, Heart_failure_Intervention_Evidence_from_MAGICapp_313881, Heart_failure_Intervention_Evidence_from_MAGICapp_313961, Heart_failure_from_MAGICapp_313881, Heart_failure_from_MAGICapp_313961, Height_with_comparator, Height_with_intervention, High_Blood_Pressure_Medication_Value_Set, History_of_Acrophobia, History_of_Acrophobia_with_comparator, History_of_Acrophobia_with_intervention, History_of_Broken_Bones, History_of_Broken_Bones_with_comparator, History_of_Broken_Bones_with_intervention, History_of_Parachute_Use, History_of_Parachute_Use_with_comparator, History_of_Parachute_Use_with_intervention, Hypertension_Control_at_12_weeks, ICD10GM_Terminale_Codes, IV_remdesivir_200_mg_then_100_mg_day_for_9_days, Injury_Severity_Score_30_days_after_Impact_comparing_intervention_vs_comparator, Injury_Severity_Score_30_days_after_Impact_with_comparator, Injury_Severity_Score_30_days_after_Impact_with_intervention, Injury_Severity_Score_on_Impact_comparing_intervention_vs_comparator, Injury_Severity_Score_on_Impact_with_comparator, Injury_Severity_Score_on_Impact_with_intervention, International_vs_Domestic_Flight, International_vs_Domestic_Flight_with_comparator, International_vs_Domestic_Flight_with_intervention, InterventionOnlyEvidence_Additional_GI_surgical_procedure_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_New_onset_depression_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Remission_of_diabetes_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Treatment_with_opioids_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, Investigator, Investigator_by_treatment_interaction_for_ADAS_Cog11_ANCOVA, LBDGLUSI, LBXGLU, Library/179606, Library/179618, Library/179632, List/179470, List/179579, List/179585, List/179800, List/307202, List/307246, List/307247, List/312201, List/312205, List/375184, MeanDiffA1c2016metaAnalysis, Mean_Change_in_Blood_Urea_Nitrogen_NCT03640312, Mean_Change_in_Serum_Creatinine_NCT03640312, Mean_Change_in_Serum_Potassium_NCT03640312, Mean_Change_in_Serum_Sodium_NCT03640312, Mean_Diastolic_Blood_Pressure_NCT03640312, Mean_Systolic_Blood_Pressure_NCT03640312, Median_Age_SD, Medication_Adherence_NCT03640312, Medication_Adherence_at_12_weeks, MetaanalysisEligibilityCriteria_Mean_difference_in_HbA1c_effect_of_bariatric_surgery_in_type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis, MetaanalysisOutcomeDefinition_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_at_end_of_follow_up, MetaanalysisStudyGroup_Effect_Estimates_for_Mortality_at_14_days_from_COVID19_Remdesivir_vs_Placebo_RCTs, Mortality14Day, NCT03421379_Eligibility_Criteria, NCT03421379_FHIR_Transform, NCT03421379_FHIR_Transform_M11_IGBJ, NCT03421379_Results, NCT03421379_primaryOutcomeMeasure_0_OG000, NCT03421379_primaryOutcomeMeasure_0_OG001, NCT03421379_primaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001, NCT03421379_secondaryOutcomeMeasure_0_OG000, NCT03421379_secondaryOutcomeMeasure_0_OG001, NCT03421379_secondaryOutcomeMeasure_1_OG000, NCT03421379_secondaryOutcomeMeasure_1_OG001, NCT03421379_secondaryOutcomeMeasure_2_OG000, NCT03421379_secondaryOutcomeMeasure_2_OG001, NCT03421379_secondaryOutcomeMeasure_3_OG000, NCT03421379_secondaryOutcomeMeasure_3_OG001, NCT03421379_secondaryOutcomeMeasure_4_OG000, NCT03421379_secondaryOutcomeMeasure_4_OG001, NCT03640312_Eligibility_Criteria, NCT03640312_FHIR_Transform, NCT03640312_Results, NCT03640312_otherOutcomeMeasure_0_OG000, NCT03640312_otherOutcomeMeasure_0_OG001, NCT03640312_otherOutcomeMeasure_0_OutcomeAnalysis_11_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_1_OG000, NCT03640312_otherOutcomeMeasure_1_OG001, NCT03640312_otherOutcomeMeasure_1_OutcomeAnalysis_12_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_2_OG000, NCT03640312_otherOutcomeMeasure_2_OG001, NCT03640312_otherOutcomeMeasure_2_OutcomeAnalysis_13_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_3_OG000, NCT03640312_otherOutcomeMeasure_3_OG001, NCT03640312_otherOutcomeMeasure_3_OutcomeAnalysis_14_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_4_OG000, NCT03640312_otherOutcomeMeasure_4_OG001, NCT03640312_otherOutcomeMeasure_4_OutcomeAnalysis_15_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_5_OG000, NCT03640312_otherOutcomeMeasure_5_OG001, NCT03640312_otherOutcomeMeasure_5_OutcomeAnalysis_16_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_6_OG000, NCT03640312_otherOutcomeMeasure_6_OG001, NCT03640312_otherOutcomeMeasure_6_OutcomeAnalysis_17_BetweenGroupAnalysis_OG000_OG001, NCT03640312_primaryOutcomeMeasure_0_OG000, NCT03640312_primaryOutcomeMeasure_0_OG001, NCT03640312_primaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_0_OG000, NCT03640312_secondaryOutcomeMeasure_0_OG001, NCT03640312_secondaryOutcomeMeasure_0_OutcomeAnalysis_1_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_1_OG000, NCT03640312_secondaryOutcomeMeasure_1_OG001, NCT03640312_secondaryOutcomeMeasure_1_OutcomeAnalysis_2_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_2_OG000, NCT03640312_secondaryOutcomeMeasure_2_OG001, NCT03640312_secondaryOutcomeMeasure_2_OutcomeAnalysis_3_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_3_12_weeks_OG000, NCT03640312_secondaryOutcomeMeasure_3_12_weeks_OG001, NCT03640312_secondaryOutcomeMeasure_3_6_weeks_OG000, NCT03640312_secondaryOutcomeMeasure_3_6_weeks_OG001, NCT03640312_secondaryOutcomeMeasure_3_OutcomeAnalysis_4_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_4_OG000, NCT03640312_secondaryOutcomeMeasure_4_OG001, NCT03640312_secondaryOutcomeMeasure_4_OutcomeAnalysis_5_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_5_OG000, NCT03640312_secondaryOutcomeMeasure_5_OG001, NCT03640312_secondaryOutcomeMeasure_5_OutcomeAnalysis_6_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_6_OG000, NCT03640312_secondaryOutcomeMeasure_6_OG001, NCT03640312_secondaryOutcomeMeasure_6_OutcomeAnalysis_7_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_7_Change_in_Mental_Health_T_score_OPEN_PROMIS_CLOSE_OG000, NCT03640312_secondaryOutcomeMeasure_7_Change_in_Mental_Health_T_score_OPEN_PROMIS_CLOSE_OG001, NCT03640312_secondaryOutcomeMeasure_7_Change_in_Physical_Health_T_score_OPEN_PROMIS_CLOSE_OG000, NCT03640312_secondaryOutcomeMeasure_7_Change_in_Physical_Health_T_score_OPEN_PROMIS_CLOSE_OG001, NCT03640312_secondaryOutcomeMeasure_7_OutcomeAnalysis_8_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_7_OutcomeAnalysis_9_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_8_OG000, NCT03640312_secondaryOutcomeMeasure_8_OG001, NCT03640312_secondaryOutcomeMeasure_8_OutcomeAnalysis_10_BetweenGroupAnalysis_OG000_OG001, NMA_Diabetes, NTproBNP, NetEffectContribution_for_ComparativeEvidence_All_cause_mortality_effect_of_bariatric_surgery_in_2022_meta_analysis, NetEffectContribution_for_ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study, NetEffectContribution_for_ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, NetEffectContribution_for_ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, NetEffectContribution_for_ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study, NetEffectContribution_for_ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study, NetEffectContributions_Bariatric_Surgery_Example_for_GIN_2022, NetEffectEstimate_for_SummaryOfNetEffect_Bariatric_Surgery_Summary_of_Net_Effect_Contributions_Example_for_GIN_2022, Nonfatal_myocardial_infarction313878, Nonfatal_myocardial_infarction313958, Nonfatal_myocardial_infarction_Comparator_Evidence_from_MAGICapp_313878, Nonfatal_myocardial_infarction_Comparator_Evidence_from_MAGICapp_313958, Nonfatal_myocardial_infarction_Intervention_Evidence_from_MAGICapp_313878, Nonfatal_myocardial_infarction_Intervention_Evidence_from_MAGICapp_313958, Nonfatal_myocardial_infarction_from_MAGICapp_313878, Nonfatal_myocardial_infarction_from_MAGICapp_313958, Nonfatal_stroke313879, Nonfatal_stroke313959, Nonfatal_stroke_Comparator_Evidence_from_MAGICapp_313879, Nonfatal_stroke_Comparator_Evidence_from_MAGICapp_313959, Nonfatal_stroke_Intervention_Evidence_from_MAGICapp_313879, Nonfatal_stroke_Intervention_Evidence_from_MAGICapp_313959, Nonfatal_stroke_from_MAGICapp_313879, Nonfatal_stroke_from_MAGICapp_313959, Ntprobnp_comparator, Ntprobnp_date, Ntprobnp_time, Ntprobnp_unit, Number_of_Patients_Requiring_Step_up_Treatment_NCT03640312, Organ_support_free_days, OutcomeDefinition_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control, OutcomeDefinition_Diabetes_in_remission, OutcomeDefinition_HbA1c_at_12_months, OutcomeDefinition_HbA1c_at_24_months, OutcomeDefinition_HbA1c_at_36_months, OutcomeDefinition_HbA1c_at_60_months, OutcomeDefinition_HbA1c_at_6_months, OutcomeDefinition_New_onset_depression, OutcomeDefinition_Nonfatal_myocardial_infarction_or_stroke, OutcomeVariable_Additional_GI_surgical_procedure, OutcomeVariable_All_cause_mortality, OutcomeVariable_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control_at_5_years, OutcomeVariable_HbA1c_at_12_months, OutcomeVariable_HbA1c_at_24_months, OutcomeVariable_HbA1c_at_36_months, OutcomeVariable_HbA1c_at_60_months, OutcomeVariable_HbA1c_at_6_months, OutcomeVariable_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_at_end_of_follow_up, OutcomeVariable_New_onset_depression, OutcomeVariable_Nonfatal_myocardial_infarction_or_stroke, OutcomeVariable_Remission_of_diabetes, OutcomeVariable_Treatment_with_opioids, Outcome_Death_or_Major_Traumatic_Injury_30_days_after_Impact, Outcome_Death_or_Major_Traumatic_Injury_on_Impact, Outcome_Injury_Severity_Score_30_days_after_Impact, Outcome_Injury_Severity_Score_on_Impact, PARACHUTE_Trial_Participants_available_for_randomization, PARACHUTE_Trial_Participants_deemed_unsuitable_by_investigator, PARACHUTE_Trial_Participants_randomized_into_groups, PARACHUTE_Trial_Participants_randomized_into_groups_for_screened_group, PARACHUTE_Trial_Participants_randomized_into_groups_with_comparator, PARACHUTE_Trial_Participants_randomized_into_groups_with_intervention, PARACHUTE_Trial_Participants_that_completed_30_day_follow_up, PARACHUTE_Trial_Participants_that_completed_30_day_follow_up_with_comparator, PARACHUTE_Trial_Participants_that_completed_30_day_follow_up_with_intervention, PARACHUTE_Trial_Participants_that_completed_jump_and_5_minute_follow_up, PARACHUTE_Trial_Participants_that_completed_jump_and_5_minute_follow_up_with_comparator, PARACHUTE_Trial_Participants_that_completed_jump_and_5_minute_follow_up_with_intervention, PARACHUTE_Trial_Participants_that_declined_randomization, PARACHUTE_Trial_Participants_with_no_contact_at_30_days, PARACHUTE_Trial_Participants_with_no_contact_at_30_days_with_comparator, PARACHUTE_Trial_Participants_with_no_contact_at_30_days_with_intervention, PD_Time_to_Maximal_Concentration_Tmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_IM_NCT03421379, PK_Change_From_Baseline_in_Maximal_Concentration_Cmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_IM_NCT03421379, PK_Change_From_Baseline_in_Tmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_IM_NCT03421379, Parachute_vs_Empty_Backpack_in_PARACHUTE_Trial, ParticipantFlowEvidence_2018_Norwegian_Cohort_Excluded_from_Analysis, ParticipantFlowMeasure_Dropout_due_to_stopping_intervention, ParticipantFlowMeasure_Exclusion_from_analysis, ParticipantFlowMeasure_Inclusion_in_analysis, ParticipantFlow_2018_Norwegian_Cohort_Included_in_Analysis, ParticipantFlow_2018_Norwegian_Cohort_Medical_Group_Included_in_Analysis, ParticipantFlow_2018_Norwegian_Cohort_Surgical_Group_Included_in_Analysis, Participants_Excluded_from_PARACHUTE_Study, Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill, Patient_id, Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill, Percentage_of_Participants_Achieving_Treatment_Success_During_Controlled_Insulin_Induced_Hypoglycemia_NCT03421379, Percentage_of_Participants_With_Potentially_Related_Adverse_Events_NCT03640312, Percentage_of_Participants_With_Serious_Adverse_Events_SAEs_NCT03640312, Pharmacodynamics_PD_Change_From_Baseline_in_Maximal_Blood_Glucose_BGmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_Intramuscular_IM_NCT03421379, Pharmacokinetics_PK_Change_From_Baseline_in_Area_Under_the_Concentration_Versus_Time_Curve_From_Zero_to_Time_t_AUC_0_tLast_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_IM_NCT03421379, Placebo, PlanDefinition/179468, PlanDefinition/179554, PlanDefinition/181450, Proportion_of_Patients_With_Adverse_Event_Free_Hypertension_Control_NCT03640312, Proportion_of_Patients_With_Hypertension_Control_NCT03640312, Proportion_of_Patients_With_Hypertension_Control_at_6_and_12_weeks_12_weeks_at_NCT03640312, Proportion_of_Patients_With_Hypertension_Control_at_6_and_12_weeks_6_weeks_at_NCT03640312, QUARTET_Eligibility_Criteria, Randomized_into_groups_for_PARACHUTE_Trial, Rate_of_Adverse_Events_of_Special_Interest_NCT03640312, Rate_of_Death_or_Major_Traumatic_Injury_on_Impact_with_comparator, Rate_of_Death_or_Major_Traumatic_Injury_on_Impact_with_intervention, Reasons_for_exclusion_from_QUARTET_USA_Trial, Remdesivir, Remdesivir_IV_200_mg_once_then_100_mg_once_daily_for_9_days, ResearchStudyClassifierCodeSystem, Risk_of_bias_type, SEQN, Sample_ID, SearchStrategy_PubMed_and_Embase_search_for_van_Veldhuisen_2022_systematic_review, SearchStrategy_PubMed_search_for_Wonder_Woman, Self_reported_race, Self_reported_sex, Serious_hyperglycaemia313882, Serious_hyperglycaemia313963, Serious_hyperglycaemia_Comparator_Evidence_from_MAGICapp_313882, Serious_hyperglycaemia_Comparator_Evidence_from_MAGICapp_313963, Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313882, Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313963, Serious_hyperglycaemia_from_MAGICapp_313882, Serious_hyperglycaemia_from_MAGICapp_313963, Severe_gastrointestinal_events313883, Severe_gastrointestinal_events313965, Severe_gastrointestinal_events_Comparator_Evidence_from_MAGICapp_313883, Severe_gastrointestinal_events_Comparator_Evidence_from_MAGICapp_313965, Severe_gastrointestinal_events_Intervention_Evidence_from_MAGICapp_313883, Severe_gastrointestinal_events_Intervention_Evidence_from_MAGICapp_313965, Severe_gastrointestinal_events_from_MAGICapp_313883, Severe_gastrointestinal_events_from_MAGICapp_313965, Severely_Obese_Adults_2018_Norwegian_Cohort, Sex, Sex_with_comparator, Sex_with_intervention, Sodium_Glucose_Transport_Protein_2_SGLT2_inhibitors85394_I_85798, Source_of_sample, Spanish_or_English_Value_Set, Standard_care85390_C_85789, StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study, StudyEligibilityCriteria_Eligibility_Criteria_for_DIBASY_Trial, StudyEligibilityCriteria_Obese_patients_18_years_old, StudyGroup_Bariatric_Surgery_Trial_Enrollment_Group, StudyGroup_DIBASY_Trial_Enrollment_Group, Subject_ID, Subject_age_at_diagnosis, SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer, Systolic_blood_pressure_at_12_weeks, Technology_employed_on_the_sample, The_tumor_status_of_the_sample, Therapeutic_dose_anticoagulation_with_heparin_vs_Usual_care_pharmacologic_thromboprophylaxis, Time_to_integration_of_results_in_a_recommendation, Type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis, Velocity, Velocity_comparing_intervention_vs_comparator, Velocity_for_enrolled_group, Velocity_for_non_participant_group, Velocity_with_comparator, Velocity_with_intervention, WTSAF2YR, Weight, Weight_with_comparator, Weight_with_intervention and Year_2018_Norwegian_Cohort_Study * GTSAbbreviation: ActivityDefinition/375159 and ActivityDefinition/375181 * EvidenceVariableRole: Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY ( src )

author: Brian S. Alper: , Computable Publishing®: MEDLINE-to-FEvIR Converter: ( src )

author: Brian S. Alper: , Computable Publishing®: MEDLINE-to-FEvIR Converter: , Joanne Dehnbostel: ( src )

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: ( src )

author: Computable Publishing®: MAGIC-to-FEvIR Converter: ( src )

author: Computable Publishing®: MEDLINE-to-FEvIR Converter: ( src )

suggested alternative name: GlucaGen® ( src )

title: SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )

© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. ( src )

Type	Reference	Content
web	fevir.net	url : https://fevir.net/resources/Citation/267500
web	doi.org	url : https://doi.org/10.1186/s40360-015-0026-9
web	fevir.net	url : https://fevir.net/resources/Citation/179629
web	doi.org	url : https://doi.org/10.1007/s00280-013-2163-4
web	fevir.net	url : https://fevir.net/resources/Citation/179637
web	doi.org	url : https://doi.org/10.1016/j.drugalcdep.2008.04.002
web	fevir.net	url : https://fevir.net/resources/Citation/179597
web	doi.org	url : https://doi.org/10.1080/10894160.2018.1450001
web	fevir.net	url : https://fevir.net/resources/Citation/179625
web	doi.org	url : https://doi.org/10.1016/j.eururo.2012.03.053
web	fevir.net	url : https://fevir.net/resources/Citation/179615
web	doi.org	url : https://doi.org/10.1016/S1470-2045(12)70560-0
web	fevir.net	url : https://fevir.net/resources/Citation/179621
web	doi.org	url : https://doi.org/10.1016/S1470-2045(15)00011-X
web	fevir.net	url : https://fevir.net/resources/Citation/179605
web	fevir.net	url : https://fevir.net/resources/Citation/7636
web	fevir.net	target : https://fevir.net/resources/Citation/5192
web	www.nejm.org	target : https://www.nejm.org/doi/full/10.1056/NEJMe2111151
web	doi.org	url : https://doi.org/10.1056/NEJMoa2105911
web	www.nejm.org	url : https://www.nejm.org/doi/full/10.1056/NEJMoa2105911
web	www.nejm.org	url : https://www.nejm.org/doi/pdf/10.1056/NEJMoa2105911?articleTools=true
web	www.nejm.org	url : https://www.nejm.org/doi/suppl/10.1056/NEJMoa2105911/suppl_file/nejmoa2105911_appendix.pdf
web	fevir.net	url : https://fevir.net/resources/Citation/33399
web	doi.org	url : https://doi.org/10.1093/eurheartj/ehac071
web	fevir.net	url : https://fevir.net/resources/Citation/264329
web	doi.org	url : https://doi.org/10.1136/bmj-2022-074068
web	fevir.net	url : https://fevir.net/resources/Citation/121719
web	doi.org	url : https://doi.org/10.17226/10027
web	fevir.net	url : https://fevir.net/resources/Citation/139860
web	fevir.net	url : https://fevir.net/resources/Citation/139859
web	fevir.net	baseCitation : BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
web	fevir.net	url : https://fevir.net/resources/Citation/179604
web	fevir.net	url : https://fevir.net/resources/Citation/179628
web	fevir.net	url : https://fevir.net/resources/Citation/179616
web	doi.org	url : https://doi.org/10.1056/NEJMoa1503747
web	fevir.net	url : https://fevir.net/resources/Citation/247416
web	fevir.net	url : https://fevir.net/FLI/DocumentForComposition178426
web	fevir.net	url : https://fevir.net/resources/Composition/178426
web	fevir.net	url : https://fevir.net/resources/Citation/385938
web	fevir.net	url : https://fevir.net/resources/Citation/7638
web	fevir.net	https://fevir.net/resources/Citation/7636
web	fevir.net	url : https://fevir.net/resources/Evidence/7637
web	fevir.net	url : https://fevir.net/resources/Citation/58
web	fevir.net	url : https://fevir.net/resources/Evidence/55
web	fevir.net	url : https://fevir.net/resources/Citation/179626
web	doi.org	url : https://doi.org/10.1016/S0140-6736(11)61095-7
web	fevir.net	url : https://fevir.net/resources/Citation/29812
web	fevir.net	url : https://fevir.net/
web	fevir.net	url : https://fevir.net/resources/Project/29394
web	fevir.net	url : https://fevir.net/resources/Citation/179558
web	fevir.net	https://fevir.net/resources/Composition/178426
web	fevir.net	url : https://fevir.net/resources/Citation/179559
web	fevir.net	url : https://fevir.net/resources/Citation/267496
web	fevir.net	url : https://fevir.net/resources/Citation/153881
web	doi.org	url : https://doi.org/10.1016/S0140-6736(22)00538-4
web	fevir.net	url : https://fevir.net/resources/Citation/367878
web	doi.org	url : https://doi.org/10.1038/s41440-024-01658-y
web	fevir.net	url : https://fevir.net/resources/Citation/179613
web	doi.org	url : https://doi.org/10.1371/journal.pone.0157660
web	fevir.net	url : https://fevir.net/resources/Citation/112
web	www.medrxiv.org	url : https://www.medrxiv.org/content/10.1101/2020.08.13.20174201v1
web	www.medrxiv.org	url : https://www.medrxiv.org/content/10.1101/2020.08.13.20174201v1.full.pdf
web	fevir.net	url : https://fevir.net/resources/Citation/267498
web	doi.org	url : https://doi.org/10.1089/dia.2015.0451
web	fevir.net	url : https://fevir.net/resources/Citation/179627
web	doi.org	url : https://doi.org/10.1016/S0140-6736(08)61815-2
web	fevir.net	url : https://fevir.net/resources/Citation/179630
web	doi.org	url : https://doi.org/10.1016/j.urolonc.2015.05.012
web	fevir.net	url : https://fevir.net/resources/Citation/179595
web	doi.org	url : https://doi.org/10.1126/science.362.6417.966
web	fevir.net	url : https://fevir.net/resources/Citation/267497
web	fevir.net	url : https://fevir.net/resources/Citation/267501
web	doi.org	url : https://doi.org/10.2337/dc12-2480
web	fevir.net	url : https://fevir.net/resources/Citation/179599
web	doi.org	url : https://doi.org/10.1123/jsep.2017-0028
web	fevir.net	url : https://fevir.net/resources/Citation/267499
web	doi.org	url : https://doi.org/10.2337/dc15-1498
web	fevir.net	url : https://fevir.net/resources/Citation/179596
web	doi.org	url : https://doi.org/10.1080/10894160.2018.1449500
web	fevir.net	url : https://fevir.net/resources/Citation/32137
web	doi.org	url : https://doi.org/10.2337/dc21-S008
web	fevir.net	url : https://fevir.net/resources/Citation/104116
web	doi.org	url : https://doi.org/10.1001/jama.2017.21055
web	fevir.net	url : https://fevir.net/resources/Citation/179623
web	doi.org	url : https://doi.org/10.1016/j.urology.2012.12.025
web	fevir.net	url : https://fevir.net/resources/Citation/179624
web	doi.org	url : https://doi.org/10.1186/1756-8722-7-20
web	fevir.net	url : https://fevir.net/resources/Citation/33089
web	doi.org	url : https://doi.org/10.2337/dc16-0236
web	fevir.net	url : https://fevir.net/resources/Citation/306957
web	doi.org	url : https://doi.org/10.1136/bmj.k5094
web	fevir.net	url : https://fevir.net/resources/Citation/179631
web	doi.org	url : https://doi.org/10.1200/JCO.2007.15.9830
web	fevir.net	url : https://fevir.net/resources/Citation/5296
web	fevir.net	target : https://fevir.net/resources/Evidence/6513
web	fevir.net	target : https://fevir.net/resources/Evidence/6514
web	fevir.net	target : https://fevir.net/resources/Evidence/6512
web	doi.org	url : https://doi.org/10.31219/osf.io/urb6f
web	osf.io	url : https://osf.io/urb6f/
web	fevir.net	url : https://fevir.net/resources/Citation/267246
web	fevir.net	url : https://fevir.net/resources/Citation/179622
web	doi.org	url : https://doi.org/10.1093/annonc/mdv245
web	fevir.net	url : https://fevir.net/resources/Citation/179560
web	fevir.net	url : https://fevir.net/ctgovconvert
web	fevir.net	url : https://fevir.net/resources/Project/29885
web	fevir.net	url : https://fevir.net/resources/Citation/267247
web	fevir.net	url : https://fevir.net/resources/Citation/33400
web	fevir.net	url : https://fevir.net/resources/Citation/179617
web	doi.org	url : https://doi.org/10.1016/j.eururo.2014.09.032
web	fevir.net	url : https://fevir.net/resources/Citation/179598
web	doi.org	url : https://doi.org/10.1152/advan.00161.2017
web	fevir.net	url : https://fevir.net/resources/Citation/179601
web	doi.org	url : https://doi.org/10.7326/W17-0068
web	fevir.net	url : https://fevir.net/resources/Citation/179600
web	doi.org	url : https://doi.org/10.7326/W17-0069
web	fevir.net	url : https://fevir.net/resources/Citation/179561
web	fevir.net	url : https://fevir.net/resources/Citation/179594
web	doi.org	url : https://doi.org/10.1016/j.jacr.2021.10.014
web	fevir.net	url : https://fevir.net/resources/Citation/179602
web	fevir.net	url : https://fevir.net/resources/Citation/179603
web	fevir.net	url : https://fevir.net/resources/Composition/370505
web	fevir.net	url : https://fevir.net/resources/Composition/399874
web	fevir.net	url : https://fevir.net/resources/Composition/399872
web	fevir.net	url : https://fevir.net/resources/Composition/370503
web	fevir.net	url : https://fevir.net/resources/Composition/370510
web	fevir.net	url : https://fevir.net/resources/Composition/312203
web	fevir.net	url : https://fevir.net/resources/Composition/372776
web	fevir.net	url : https://fevir.net/resources/Composition/236538
web	fevir.net	url : https://fevir.net/resources/Composition/179465
web	fevir.net	url : https://fevir.net/resources/Composition/256358
web	fevir.net	url : https://fevir.net/resources/Composition/343018
web	fevir.net	url : https://fevir.net/resources/Composition/318262
web	fevir.net	url : https://fevir.net/resources/Composition/399873
web	fevir.net	url : https://fevir.net/resources/Composition/370504
web	fevir.net	url : https://fevir.net/resources/Composition/343007
web	fevir.net	url : https://fevir.net/resources/Composition/307245
web	fevir.net	url : https://fevir.net/resources/Composition/307248
web	fevir.net	url : https://fevir.net/resources/Composition/312172
web	fevir.net	url : https://fevir.net/resources/Composition/292951
web	fevir.net	url : https://fevir.net/resources/Composition/399871
web	fevir.net	url : https://fevir.net/resources/Composition/370502
web	fevir.net	url : https://fevir.net/resources/Composition/370512
web	fevir.net	url : https://fevir.net/resources/Composition/179467
web	fevir.net	url : https://fevir.net/resources/Composition/179699
web	fevir.net	url : https://fevir.net/resources/Composition/179466
web	fevir.net	url : https://fevir.net/resources/Composition/267224
web	fevir.net	url : https://fevir.net/resources/Composition/367880
web	fevir.net	url : https://fevir.net/resources/Composition/236537
web	fevir.net	url : https://fevir.net/resources/Composition/236951
web	fevir.net	url : https://fevir.net/resources/Evidence/307430
web	fevir.net	url : https://fevir.net/resources/Evidence/307447
web	fevir.net	url : https://fevir.net/resources/Evidence/307444
web	fevir.net	url : https://fevir.net/resources/Evidence/307251
web	fevir.net	url : https://fevir.net/resources/Evidence/307250
web	fevir.net	url : https://fevir.net/resources/Evidence/367908
web	fevir.net	url : https://fevir.net/resources/Evidence/367943
web	fevir.net	url : https://fevir.net/resources/Evidence/367907
web	fevir.net	url : https://fevir.net/resources/Evidence/367904
web	fevir.net	url : https://fevir.net/resources/Evidence/367951
web	fevir.net	url : https://fevir.net/resources/Evidence/367903
web	fevir.net	url : https://fevir.net/resources/Evidence/367925
web	fevir.net	url : https://fevir.net/resources/Evidence/367926
web	fevir.net	url : https://fevir.net/resources/Evidence/367941
web	fevir.net	url : https://fevir.net/resources/Evidence/32144
web	fevir.net	url : https://fevir.net/resources/Evidence/104157
web	jamanetwork.com	https://jamanetwork.com/journals/jama/fullarticle/2669729
web	fevir.net	url : https://fevir.net/resources/Evidence/104156
web	fevir.net	url : https://fevir.net/resources/Evidence/104098
web	jamanetwork.com	https://jamanetwork.com/journals/jama/fullarticle/1103994
web	fevir.net	url : https://fevir.net/resources/Evidence/104155
web	fevir.net	url : https://fevir.net/resources/Evidence/104121
web	fevir.net	url : https://fevir.net/resources/Evidence/47740
web	fevir.net	url : https://fevir.net/resources/Evidence/47768
web	fevir.net	url : https://fevir.net/resources/Evidence/47771
web	fevir.net	url : https://fevir.net/resources/Evidence/47665
web	fevir.net	url : https://fevir.net/resources/Evidence/47749
web	fevir.net	url : https://fevir.net/resources/Evidence/47752
web	fevir.net	url : https://fevir.net/resources/Evidence/47766
web	fevir.net	url : https://fevir.net/resources/Evidence/47748
web	fevir.net	url : https://fevir.net/resources/Evidence/47751
web	fevir.net	url : https://fevir.net/resources/Evidence/47695
web	fevir.net	url : https://fevir.net/resources/Evidence/47738
web	fevir.net	url : https://fevir.net/resources/Evidence/47758
web	fevir.net	url : https://fevir.net/resources/Evidence/47759
web	fevir.net	url : https://fevir.net/resources/Evidence/47760
web	fevir.net	url : https://fevir.net/resources/Evidence/47762
web	fevir.net	url : https://fevir.net/resources/Evidence/318273
web	fevir.net	url : https://fevir.net/resources/Evidence/307454
web	fevir.net	url : https://fevir.net/resources/Evidence/379739
web	fevir.net	url : https://fevir.net/resources/Evidence/379740
web	fevir.net	url : https://fevir.net/resources/Evidence/379741
web	fevir.net	url : https://fevir.net/resources/Evidence/397479
web	fevir.net	url : https://fevir.net/resources/Evidence/379738
web	fevir.net	url : https://fevir.net/resources/Evidence/397480
web	fevir.net	url : https://fevir.net/resources/Evidence/379725
web	fevir.net	url : https://fevir.net/resources/Evidence/397483
web	fevir.net	url : https://fevir.net/resources/Evidence/307453
web	fevir.net	url : https://fevir.net/resources/Evidence/367921
web	fevir.net	url : https://fevir.net/resources/Evidence/367922
web	fevir.net	url : https://fevir.net/resources/Evidence/367924
web	fevir.net	url : https://fevir.net/resources/Evidence/367923
web	fevir.net	url : https://fevir.net/resources/Evidence/367950
web	fevir.net	url : https://fevir.net/resources/Evidence/367949
web	fevir.net	url : https://fevir.net/resources/Evidence/236955
web	fevir.net	url : https://fevir.net/resources/Evidence/236541
web	fevir.net	url : https://fevir.net/resources/Evidence/236568
web	fevir.net	url : https://fevir.net/resources/Evidence/236988
web	fevir.net	url : https://fevir.net/resources/Evidence/236544
web	fevir.net	url : https://fevir.net/resources/Evidence/236958
web	fevir.net	url : https://fevir.net/resources/Evidence/236973
web	fevir.net	url : https://fevir.net/resources/Evidence/236553
web	fevir.net	url : https://fevir.net/resources/Evidence/236967
web	fevir.net	url : https://fevir.net/resources/Evidence/236979
web	fevir.net	url : https://fevir.net/resources/Evidence/236985
web	fevir.net	url : https://fevir.net/resources/Evidence/236565
web	fevir.net	url : https://fevir.net/resources/Evidence/236556
web	fevir.net	url : https://fevir.net/resources/Evidence/236970
web	fevir.net	url : https://fevir.net/resources/Evidence/236550
web	fevir.net	url : https://fevir.net/resources/Evidence/236547
web	fevir.net	url : https://fevir.net/resources/Evidence/236961
web	fevir.net	url : https://fevir.net/resources/Evidence/236964
web	fevir.net	url : https://fevir.net/resources/Evidence/236976
web	fevir.net	url : https://fevir.net/resources/Evidence/236559
web	fevir.net	url : https://fevir.net/resources/Evidence/236562
web	fevir.net	url : https://fevir.net/resources/Evidence/236982
web	fevir.net	url : https://fevir.net/resources/Evidence/236540
web	fevir.net	url : https://fevir.net/resources/Evidence/236954
web	fevir.net	url : https://fevir.net/resources/Evidence/236567
web	fevir.net	url : https://fevir.net/resources/Evidence/236987
web	fevir.net	url : https://fevir.net/resources/Evidence/236543
web	fevir.net	url : https://fevir.net/resources/Evidence/236957
web	fevir.net	url : https://fevir.net/resources/Evidence/236972
web	fevir.net	url : https://fevir.net/resources/Evidence/236552
web	fevir.net	url : https://fevir.net/resources/Evidence/236966
web	fevir.net	url : https://fevir.net/resources/Evidence/236978
web	fevir.net	url : https://fevir.net/resources/Evidence/236564
web	fevir.net	url : https://fevir.net/resources/Evidence/236984
web	fevir.net	url : https://fevir.net/resources/Evidence/236969
web	fevir.net	url : https://fevir.net/resources/Evidence/236555
web	fevir.net	url : https://fevir.net/resources/Evidence/236546
web	fevir.net	url : https://fevir.net/resources/Evidence/236960
web	fevir.net	url : https://fevir.net/resources/Evidence/236549
web	fevir.net	url : https://fevir.net/resources/Evidence/236963
web	fevir.net	url : https://fevir.net/resources/Evidence/236558
web	fevir.net	url : https://fevir.net/resources/Evidence/236975
web	fevir.net	url : https://fevir.net/resources/Evidence/236561
web	fevir.net	url : https://fevir.net/resources/Evidence/236981
web	fevir.net	url : https://fevir.net/resources/Evidence/293872
web	fevir.net	url : https://fevir.net/resources/Evidence/293980
web	fevir.net	url : https://fevir.net/resources/Evidence/293881
web	fevir.net	url : https://fevir.net/resources/Evidence/293991
web	fevir.net	url : https://fevir.net/resources/Evidence/293873
web	fevir.net	url : https://fevir.net/resources/Evidence/293981
web	fevir.net	url : https://fevir.net/resources/Evidence/293986
web	fevir.net	url : https://fevir.net/resources/Evidence/293876
web	fevir.net	url : https://fevir.net/resources/Evidence/293984
web	fevir.net	url : https://fevir.net/resources/Evidence/293988
web	fevir.net	url : https://fevir.net/resources/Evidence/293877
web	fevir.net	url : https://fevir.net/resources/Evidence/293880
web	fevir.net	url : https://fevir.net/resources/Evidence/293985
web	fevir.net	url : https://fevir.net/resources/Evidence/293990
web	fevir.net	url : https://fevir.net/resources/Evidence/293874
web	fevir.net	url : https://fevir.net/resources/Evidence/293982
web	fevir.net	url : https://fevir.net/resources/Evidence/293875
web	fevir.net	url : https://fevir.net/resources/Evidence/293983
web	fevir.net	url : https://fevir.net/resources/Evidence/293987
web	fevir.net	url : https://fevir.net/resources/Evidence/293878
web	fevir.net	url : https://fevir.net/resources/Evidence/293989
web	fevir.net	url : https://fevir.net/resources/Evidence/293879
web	fevir.net	url : https://fevir.net/resources/Evidence/367937
web	fevir.net	url : https://fevir.net/resources/Evidence/367957
web	fevir.net	url : https://fevir.net/resources/Evidence/367938
web	fevir.net	url : https://fevir.net/resources/Evidence/367940
web	fevir.net	url : https://fevir.net/resources/Evidence/367939
web	fevir.net	url : https://fevir.net/resources/Evidence/367958
web	fevir.net	url : https://fevir.net/resources/Evidence/367933
web	fevir.net	url : https://fevir.net/resources/Evidence/367934
web	fevir.net	url : https://fevir.net/resources/Evidence/367955
web	fevir.net	url : https://fevir.net/resources/Evidence/367936
web	fevir.net	url : https://fevir.net/resources/Evidence/367935
web	fevir.net	url : https://fevir.net/resources/Evidence/367956
web	fevir.net	url : https://fevir.net/resources/Evidence/367909
web	fevir.net	url : https://fevir.net/resources/Evidence/367910
web	fevir.net	url : https://fevir.net/resources/Evidence/367944
web	fevir.net	url : https://fevir.net/resources/Evidence/367906
web	fevir.net	url : https://fevir.net/resources/Evidence/367905
web	fevir.net	url : https://fevir.net/resources/Evidence/367942
web	fevir.net	url : https://fevir.net/resources/Evidence/367920
web	fevir.net	url : https://fevir.net/resources/Evidence/367919
web	fevir.net	url : https://fevir.net/resources/Evidence/367948
web	fevir.net	url : https://fevir.net/resources/Evidence/179587
web	fevir.net	url : https://fevir.net/resources/Evidence/179589
web	fevir.net	url : https://fevir.net/resources/Evidence/179588
web	fevir.net	url : https://fevir.net/resources/Evidence/179591
web	fevir.net	url : https://fevir.net/resources/Evidence/179590
web	fevir.net	url : https://fevir.net/resources/Evidence/179586
web	fevir.net	url : https://fevir.net/resources/Evidence/423311
web	fevir.net	url : https://fevir.net/resources/Evidence/367915
web	fevir.net	url : https://fevir.net/resources/Evidence/367916
web	fevir.net	url : https://fevir.net/resources/Evidence/367946
web	fevir.net	url : https://fevir.net/resources/Evidence/307455
web	fevir.net	url : https://fevir.net/resources/Evidence/312166
web	fevir.net	url : https://fevir.net/resources/Evidence/312161
web	fevir.net	url : https://fevir.net/resources/Evidence/312162
web	fevir.net	url : https://fevir.net/resources/Evidence/312165
web	fevir.net	url : https://fevir.net/resources/Evidence/312163
web	fevir.net	url : https://fevir.net/resources/Evidence/312164
web	fevir.net	url : https://fevir.net/resources/Evidence/179462
web	fevir.net	url : https://fevir.net/resources/Evidence/179464
web	fevir.net	url : https://fevir.net/resources/Evidence/179460
web	fevir.net	url : https://fevir.net/resources/Evidence/267236
web	fevir.net	url : https://fevir.net/resources/Evidence/267237
web	fevir.net	url : https://fevir.net/resources/Evidence/267244
web	fevir.net	url : https://fevir.net/resources/Evidence/267232
web	fevir.net	url : https://fevir.net/resources/Evidence/267233
web	fevir.net	url : https://fevir.net/resources/Evidence/367929
web	fevir.net	url : https://fevir.net/resources/Evidence/367953
web	fevir.net	url : https://fevir.net/resources/Evidence/367930
web	fevir.net	url : https://fevir.net/resources/Evidence/367927
web	fevir.net	url : https://fevir.net/resources/Evidence/367952
web	fevir.net	url : https://fevir.net/resources/Evidence/367928
web	fevir.net	url : https://fevir.net/resources/Evidence/267234
web	fevir.net	url : https://fevir.net/resources/Evidence/267235
web	fevir.net	url : https://fevir.net/resources/Evidence/267238
web	fevir.net	url : https://fevir.net/resources/Evidence/267239
web	fevir.net	url : https://fevir.net/resources/Evidence/267240
web	fevir.net	url : https://fevir.net/resources/Evidence/267241
web	fevir.net	url : https://fevir.net/resources/Evidence/267243
web	fevir.net	url : https://fevir.net/resources/Evidence/267242
web	fevir.net	url : https://fevir.net/resources/Evidence/367947
web	fevir.net	url : https://fevir.net/resources/Evidence/367918
web	fevir.net	url : https://fevir.net/resources/Evidence/367917
web	fevir.net	url : https://fevir.net/resources/Evidence/367913
web	fevir.net	url : https://fevir.net/resources/Evidence/367914
web	fevir.net	url : https://fevir.net/resources/Evidence/367945
web	fevir.net	url : https://fevir.net/resources/Evidence/367911
web	fevir.net	url : https://fevir.net/resources/Evidence/367912
web	fevir.net	url : https://fevir.net/resources/Evidence/307456
web	fevir.net	url : https://fevir.net/resources/Evidence/367954
web	fevir.net	url : https://fevir.net/resources/Evidence/367932
web	fevir.net	url : https://fevir.net/resources/Evidence/367931
web	fevir.net	url : https://fevir.net/resources/Evidence/307448
web	fevir.net	url : https://fevir.net/resources/Evidence/307443
web	fevir.net	url : https://fevir.net/resources/Evidence/307441
web	fevir.net	url : https://fevir.net/resources/Evidence/307253
web	fevir.net	url : https://fevir.net/resources/Evidence/307252
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/367884
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/367891
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/367882
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/423308
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/423306
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/423303
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/423305
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/423307
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/312202
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/236536
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/297490
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/236950
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/179784
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/370509
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/370508
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/367890
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/367901
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/367902
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/367899
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/367900
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/367885
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/367883
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/367889
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/367887
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/297743
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/306661
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/267228
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/267226
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/367897
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/367896
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/267227
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/267229
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/267230
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/267231
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/367888
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/370506
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/367886
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/370507
web	fevir.net	url : https://fevir.net/resources/EvidenceVariable/367898
web	fevir.net	url : https://fevir.net/resources/Group/236947
web	fevir.net	url : https://fevir.net/resources/Group/236533
web	fevir.net	url : https://fevir.net/resources/Group/236776
web	fevir.net	url : https://fevir.net/resources/Group/236530
web	fevir.net	url : https://fevir.net/resources/Group/12714
web	fevir.net	url : https://fevir.net/resources/Group/346486
web	fevir.net	url : https://fevir.net/resources/Group/372797
web	fevir.net	url : https://fevir.net/resources/Group/236948
web	fevir.net	url : https://fevir.net/resources/Group/236535
web	fevir.net	url : https://fevir.net/resources/Group/236532
web	fevir.net	url : https://fevir.net/resources/Group/236769
web	fevir.net	url : https://fevir.net/resources/Group/267225
web	fevir.net	url : https://fevir.net/resources/Group/367881
web	fevir.net	url : https://fevir.net/resources/Group/173251
web	fevir.net	url : https://fevir.net/resources/Group/7750
web	fevir.net	url : https://fevir.net/resources/Group/375175
web	fevir.net	url : https://fevir.net/resources/Group/236949
web	fevir.net	url : https://fevir.net/resources/Group/236534
web	fevir.net	url : https://fevir.net/resources/ResearchStudy/267223
web	fevir.net	url : https://fevir.net/resources/ResearchStudy/346485
web	euclinicaltrials.eu	target : https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-516402-32-00
web	tel:+33156016317	khalil.el-karoui@aphp.fr , +33156016317
web	fevir.net	url : https://fevir.net/resources/ResearchStudy/367879
web	github.com	Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
web	creativecommons.org	https://creativecommons.org/licenses/by-nc-sa/4.0/ Show Usage Evidence Based Medicine on FHIR Implementation Guide Code System : ADAS_Cog11_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version , Add_on_Amlodipine_at_6_weeks ... Show 375 more ResearchStudy Classifier Code System : CTIS_2024_516402_32_00_FHIR_Transform , ResearchStudyClassifier , ResearchStudySite , StudyDesign and StudyRegistryRecord
web	creativecommons.org	https://creativecommons.org/licenses/by-sa/4.0/ Show Usage Recommendation Justification Code System : All_cause_mortality_from_MAGICapp_313876 , All_cause_mortality_from_MAGICapp_313956 ... Show 25 more
web	www.iso.org	ISO maintains the copyright on the country codes, and controls its use carefully. For further details see the ISO 3166 web page: https://www.iso.org/iso-3166-country-codes.html Show Usage ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code : Year_2018_Norwegian_Cohort_Study
web	www.meddra.org	Please see https://www.meddra.org/legal-mentions . For information about special licensing, see https://www.meddra.org/subscription/special-licences Show Usage Medical Dictionary for Regulatory Activities : CTIS_2024_516402_32_00_FHIR_Transform
web	www.meddra.org	https://www.meddra.org/legal-mentions
web	www.meddra.org	Please see https://www.meddra.org/legal-mentions . For information about special licensing, see https://www.meddra.org/subscription/special-licences Show Usage Medical Dictionary for Regulatory Activities : CTIS_2024_516402_32_00_FHIR_Transform
web	www.meddra.org	https://www.meddra.org/subscription/special-licences
web	creativecommons.org	SEVCO has an open license: https://creativecommons.org/licenses/by-sa/4.0/ Copyright holder is Scientific Knowledge Accelerator Foundation. Show Usage Scientific Evidence Code System (SEVCO) : ADAS_Cog11_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version , Age_with_comparator ... Show 273 more
web	creativecommons.org	https://creativecommons.org/licenses/by-sa/4.0/
web	ucum.org	The UCUM codes, UCUM table (regardless of format), and UCUM Specification are copyright 1999-2009, Regenstrief Institute, Inc. and the Unified Codes for Units of Measures (UCUM) Organization. All rights reserved. https://ucum.org/trac/wiki/TermsOfUse Show Usage Unified Code for Units of Measure (UCUM) : ADAS_Cog11_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version , ActivityDefinition/375159 ... Show 73 more
web	fevir.net	Scientific Evidence Code System (SEVCO)
web	fevir.net	Recommendation Justification Code System
web	fevir.net	Evidence Based Medicine on FHIR Implementation Guide Code System
web	fevir.net	ResearchStudy Classifier Code System
web	fevir.net	EvidenceReportSectionCode Value Set
web	fevir.net	ResearchStudy Classifier Value Set
web	fevir.net	or use the FEvIR API .

Type

Reference

Content

web

fevir.net

url : https://fevir.net/resources/Citation/267500

web

doi.org

url : https://doi.org/10.1186/s40360-015-0026-9

web

fevir.net

url : https://fevir.net/resources/Citation/179629

web

doi.org

url : https://doi.org/10.1007/s00280-013-2163-4

web

fevir.net

url : https://fevir.net/resources/Citation/179637

web

doi.org

url : https://doi.org/10.1016/j.drugalcdep.2008.04.002

web

fevir.net

url : https://fevir.net/resources/Citation/179597

web

doi.org

url : https://doi.org/10.1080/10894160.2018.1450001

web

fevir.net

url : https://fevir.net/resources/Citation/179625

web

doi.org

url : https://doi.org/10.1016/j.eururo.2012.03.053

web

fevir.net

url : https://fevir.net/resources/Citation/179615

web

doi.org

url : https://doi.org/10.1016/S1470-2045(12)70560-0

web

fevir.net

url : https://fevir.net/resources/Citation/179621

web

doi.org

url : https://doi.org/10.1016/S1470-2045(15)00011-X

web

fevir.net

url : https://fevir.net/resources/Citation/179605

web

fevir.net

url : https://fevir.net/resources/Citation/7636

web

fevir.net

target : https://fevir.net/resources/Citation/5192

web

www.nejm.org

target : https://www.nejm.org/doi/full/10.1056/NEJMe2111151

web

doi.org

url : https://doi.org/10.1056/NEJMoa2105911

web

www.nejm.org

url : https://www.nejm.org/doi/full/10.1056/NEJMoa2105911

web

www.nejm.org

url : https://www.nejm.org/doi/pdf/10.1056/NEJMoa2105911?articleTools=true

web

www.nejm.org

url : https://www.nejm.org/doi/suppl/10.1056/NEJMoa2105911/suppl_file/nejmoa2105911_appendix.pdf

web

fevir.net

url : https://fevir.net/resources/Citation/33399

web

doi.org

url : https://doi.org/10.1093/eurheartj/ehac071

web

fevir.net

url : https://fevir.net/resources/Citation/264329

web

doi.org

url : https://doi.org/10.1136/bmj-2022-074068

web

fevir.net

url : https://fevir.net/resources/Citation/121719

web

doi.org

url : https://doi.org/10.17226/10027

web

fevir.net

url : https://fevir.net/resources/Citation/139860

web

fevir.net

url : https://fevir.net/resources/Citation/139859

web

fevir.net

baseCitation : BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century

web

fevir.net

url : https://fevir.net/resources/Citation/179604

web

fevir.net

url : https://fevir.net/resources/Citation/179628

web

fevir.net

url : https://fevir.net/resources/Citation/179616

web

doi.org

url : https://doi.org/10.1056/NEJMoa1503747

web

fevir.net

url : https://fevir.net/resources/Citation/247416

web

fevir.net

url : https://fevir.net/FLI/DocumentForComposition178426

web

fevir.net

url : https://fevir.net/resources/Composition/178426

web

fevir.net

url : https://fevir.net/resources/Citation/385938

web

fevir.net

url : https://fevir.net/resources/Citation/7638

web

fevir.net

https://fevir.net/resources/Citation/7636

web

fevir.net

url : https://fevir.net/resources/Evidence/7637

web

fevir.net

url : https://fevir.net/resources/Citation/58

web

fevir.net

url : https://fevir.net/resources/Evidence/55

web

fevir.net

url : https://fevir.net/resources/Citation/179626

web

doi.org

url : https://doi.org/10.1016/S0140-6736(11)61095-7

web

fevir.net

url : https://fevir.net/resources/Citation/29812

web

fevir.net

url : https://fevir.net/

web

fevir.net

url : https://fevir.net/resources/Project/29394

web

fevir.net

url : https://fevir.net/resources/Citation/179558

web

fevir.net

https://fevir.net/resources/Composition/178426

web

fevir.net

url : https://fevir.net/resources/Citation/179559

web

fevir.net

url : https://fevir.net/resources/Citation/267496

web

fevir.net

url : https://fevir.net/resources/Citation/153881

web

doi.org

url : https://doi.org/10.1016/S0140-6736(22)00538-4

web

fevir.net

url : https://fevir.net/resources/Citation/367878

web

doi.org

url : https://doi.org/10.1038/s41440-024-01658-y

web

fevir.net

url : https://fevir.net/resources/Citation/179613

web

doi.org

url : https://doi.org/10.1371/journal.pone.0157660

web

fevir.net

url : https://fevir.net/resources/Citation/112

web

www.medrxiv.org

url : https://www.medrxiv.org/content/10.1101/2020.08.13.20174201v1

web

www.medrxiv.org

url : https://www.medrxiv.org/content/10.1101/2020.08.13.20174201v1.full.pdf

web

fevir.net

url : https://fevir.net/resources/Citation/267498

web

doi.org

url : https://doi.org/10.1089/dia.2015.0451

web

fevir.net

url : https://fevir.net/resources/Citation/179627

web

doi.org

url : https://doi.org/10.1016/S0140-6736(08)61815-2

web

fevir.net

url : https://fevir.net/resources/Citation/179630

web

doi.org

url : https://doi.org/10.1016/j.urolonc.2015.05.012

web

fevir.net

url : https://fevir.net/resources/Citation/179595

web

doi.org

url : https://doi.org/10.1126/science.362.6417.966

web

fevir.net

url : https://fevir.net/resources/Citation/267497

web

fevir.net

url : https://fevir.net/resources/Citation/267501

web

doi.org

url : https://doi.org/10.2337/dc12-2480

web

fevir.net

url : https://fevir.net/resources/Citation/179599

web

doi.org

url : https://doi.org/10.1123/jsep.2017-0028

web

fevir.net

url : https://fevir.net/resources/Citation/267499

web

doi.org

url : https://doi.org/10.2337/dc15-1498

web

fevir.net

url : https://fevir.net/resources/Citation/179596

web

doi.org

url : https://doi.org/10.1080/10894160.2018.1449500

web

fevir.net

url : https://fevir.net/resources/Citation/32137

web

doi.org

url : https://doi.org/10.2337/dc21-S008

web

fevir.net

url : https://fevir.net/resources/Citation/104116

web

doi.org

url : https://doi.org/10.1001/jama.2017.21055

web

fevir.net

url : https://fevir.net/resources/Citation/179623

web

doi.org

url : https://doi.org/10.1016/j.urology.2012.12.025

web

fevir.net

url : https://fevir.net/resources/Citation/179624

web

doi.org

url : https://doi.org/10.1186/1756-8722-7-20

web

fevir.net

url : https://fevir.net/resources/Citation/33089

web

doi.org

url : https://doi.org/10.2337/dc16-0236

web

fevir.net

url : https://fevir.net/resources/Citation/306957

web

doi.org

url : https://doi.org/10.1136/bmj.k5094

web

fevir.net

url : https://fevir.net/resources/Citation/179631

web

doi.org

url : https://doi.org/10.1200/JCO.2007.15.9830

web

fevir.net

url : https://fevir.net/resources/Citation/5296

web

fevir.net

target : https://fevir.net/resources/Evidence/6513

web

fevir.net

target : https://fevir.net/resources/Evidence/6514

web

fevir.net

target : https://fevir.net/resources/Evidence/6512

web

doi.org

url : https://doi.org/10.31219/osf.io/urb6f

web

osf.io

url : https://osf.io/urb6f/

web

fevir.net

url : https://fevir.net/resources/Citation/267246

web

fevir.net

url : https://fevir.net/resources/Citation/179622

web

doi.org

url : https://doi.org/10.1093/annonc/mdv245

web

fevir.net

url : https://fevir.net/resources/Citation/179560

web

fevir.net

url : https://fevir.net/ctgovconvert

web

fevir.net

url : https://fevir.net/resources/Project/29885

web

fevir.net

url : https://fevir.net/resources/Citation/267247

web

fevir.net

url : https://fevir.net/resources/Citation/33400

web

fevir.net

url : https://fevir.net/resources/Citation/179617

web

doi.org

url : https://doi.org/10.1016/j.eururo.2014.09.032

web

fevir.net

url : https://fevir.net/resources/Citation/179598

web

doi.org

url : https://doi.org/10.1152/advan.00161.2017

web

fevir.net

url : https://fevir.net/resources/Citation/179601

web

doi.org

url : https://doi.org/10.7326/W17-0068

web

fevir.net

url : https://fevir.net/resources/Citation/179600

web

doi.org

url : https://doi.org/10.7326/W17-0069

web

fevir.net

url : https://fevir.net/resources/Citation/179561

web

fevir.net

url : https://fevir.net/resources/Citation/179594

web

doi.org

url : https://doi.org/10.1016/j.jacr.2021.10.014

web

fevir.net

url : https://fevir.net/resources/Citation/179602

web

fevir.net

url : https://fevir.net/resources/Citation/179603

web

fevir.net

url : https://fevir.net/resources/Composition/370505

web

fevir.net

url : https://fevir.net/resources/Composition/399874

web

fevir.net

url : https://fevir.net/resources/Composition/399872

web

fevir.net

url : https://fevir.net/resources/Composition/370503

web

fevir.net

url : https://fevir.net/resources/Composition/370510

web

fevir.net

url : https://fevir.net/resources/Composition/312203

web

fevir.net

url : https://fevir.net/resources/Composition/372776

web

fevir.net

url : https://fevir.net/resources/Composition/236538

web

fevir.net

url : https://fevir.net/resources/Composition/179465

web

fevir.net

url : https://fevir.net/resources/Composition/256358

web

fevir.net

url : https://fevir.net/resources/Composition/343018

web

fevir.net

url : https://fevir.net/resources/Composition/318262

web

fevir.net

url : https://fevir.net/resources/Composition/399873

web

fevir.net

url : https://fevir.net/resources/Composition/370504

web

fevir.net

url : https://fevir.net/resources/Composition/343007

web

fevir.net

url : https://fevir.net/resources/Composition/307245

web

fevir.net

url : https://fevir.net/resources/Composition/307248

web

fevir.net

url : https://fevir.net/resources/Composition/312172

web

fevir.net

url : https://fevir.net/resources/Composition/292951

web

fevir.net

url : https://fevir.net/resources/Composition/399871

web

fevir.net

url : https://fevir.net/resources/Composition/370502

web

fevir.net

url : https://fevir.net/resources/Composition/370512

web

fevir.net

url : https://fevir.net/resources/Composition/179467

web

fevir.net

url : https://fevir.net/resources/Composition/179699

web

fevir.net

url : https://fevir.net/resources/Composition/179466

web

fevir.net

url : https://fevir.net/resources/Composition/267224

web

fevir.net

url : https://fevir.net/resources/Composition/367880

web

fevir.net

url : https://fevir.net/resources/Composition/236537

web

fevir.net

url : https://fevir.net/resources/Composition/236951

web

fevir.net

url : https://fevir.net/resources/Evidence/307430

web

fevir.net

url : https://fevir.net/resources/Evidence/307447

web

fevir.net

url : https://fevir.net/resources/Evidence/307444

web

fevir.net

url : https://fevir.net/resources/Evidence/307251

web

fevir.net

url : https://fevir.net/resources/Evidence/307250

web

fevir.net

url : https://fevir.net/resources/Evidence/367908

web

fevir.net

url : https://fevir.net/resources/Evidence/367943

web

fevir.net

url : https://fevir.net/resources/Evidence/367907

web

fevir.net

url : https://fevir.net/resources/Evidence/367904

web

fevir.net

url : https://fevir.net/resources/Evidence/367951

web

fevir.net

url : https://fevir.net/resources/Evidence/367903

web

fevir.net

url : https://fevir.net/resources/Evidence/367925

web

fevir.net

url : https://fevir.net/resources/Evidence/367926

web

fevir.net

url : https://fevir.net/resources/Evidence/367941

web

fevir.net

url : https://fevir.net/resources/Evidence/32144

web

fevir.net

url : https://fevir.net/resources/Evidence/104157

web

jamanetwork.com

https://jamanetwork.com/journals/jama/fullarticle/2669729

web

fevir.net

url : https://fevir.net/resources/Evidence/104156

web

fevir.net

url : https://fevir.net/resources/Evidence/104098

web

jamanetwork.com

https://jamanetwork.com/journals/jama/fullarticle/1103994

web

fevir.net

url : https://fevir.net/resources/Evidence/104155

web

fevir.net

url : https://fevir.net/resources/Evidence/104121

web

fevir.net

url : https://fevir.net/resources/Evidence/47740

web

fevir.net

url : https://fevir.net/resources/Evidence/47768

web

fevir.net

url : https://fevir.net/resources/Evidence/47771

web

fevir.net

url : https://fevir.net/resources/Evidence/47665

web

fevir.net

url : https://fevir.net/resources/Evidence/47749

web

fevir.net

url : https://fevir.net/resources/Evidence/47752

web

fevir.net

url : https://fevir.net/resources/Evidence/47766

web

fevir.net

url : https://fevir.net/resources/Evidence/47748

web

fevir.net

url : https://fevir.net/resources/Evidence/47751

web

fevir.net

url : https://fevir.net/resources/Evidence/47695

web

fevir.net

url : https://fevir.net/resources/Evidence/47738

web

fevir.net

url : https://fevir.net/resources/Evidence/47758

web

fevir.net

url : https://fevir.net/resources/Evidence/47759

web

fevir.net

url : https://fevir.net/resources/Evidence/47760

web

fevir.net

url : https://fevir.net/resources/Evidence/47762

web

fevir.net

url : https://fevir.net/resources/Evidence/318273

web

fevir.net

url : https://fevir.net/resources/Evidence/307454

web

fevir.net

url : https://fevir.net/resources/Evidence/379739

web

fevir.net

url : https://fevir.net/resources/Evidence/379740

web

fevir.net

url : https://fevir.net/resources/Evidence/379741

web

fevir.net

url : https://fevir.net/resources/Evidence/397479

web

fevir.net

url : https://fevir.net/resources/Evidence/379738

web

fevir.net

url : https://fevir.net/resources/Evidence/397480

web

fevir.net

url : https://fevir.net/resources/Evidence/379725

web

fevir.net

url : https://fevir.net/resources/Evidence/397483

web

fevir.net

url : https://fevir.net/resources/Evidence/307453

web

fevir.net

url : https://fevir.net/resources/Evidence/367921

web

fevir.net

url : https://fevir.net/resources/Evidence/367922

web

fevir.net

url : https://fevir.net/resources/Evidence/367924

web

fevir.net

url : https://fevir.net/resources/Evidence/367923

web

fevir.net

url : https://fevir.net/resources/Evidence/367950

web

fevir.net

url : https://fevir.net/resources/Evidence/367949

web

fevir.net

url : https://fevir.net/resources/Evidence/236955

web

fevir.net

url : https://fevir.net/resources/Evidence/236541

web

fevir.net

url : https://fevir.net/resources/Evidence/236568

web

fevir.net

url : https://fevir.net/resources/Evidence/236988

web

fevir.net

url : https://fevir.net/resources/Evidence/236544

web

fevir.net

url : https://fevir.net/resources/Evidence/236958

web

fevir.net

url : https://fevir.net/resources/Evidence/236973

web

fevir.net

url : https://fevir.net/resources/Evidence/236553

web

fevir.net

url : https://fevir.net/resources/Evidence/236967

web

fevir.net

url : https://fevir.net/resources/Evidence/236979

web

fevir.net

url : https://fevir.net/resources/Evidence/236985

web

fevir.net

url : https://fevir.net/resources/Evidence/236565

web

fevir.net

url : https://fevir.net/resources/Evidence/236556

web

fevir.net

url : https://fevir.net/resources/Evidence/236970

web

fevir.net

url : https://fevir.net/resources/Evidence/236550

web

fevir.net

url : https://fevir.net/resources/Evidence/236547

web

fevir.net

url : https://fevir.net/resources/Evidence/236961

web

fevir.net

url : https://fevir.net/resources/Evidence/236964

web

fevir.net

url : https://fevir.net/resources/Evidence/236976

web

fevir.net

url : https://fevir.net/resources/Evidence/236559

web

fevir.net

url : https://fevir.net/resources/Evidence/236562

web

fevir.net

url : https://fevir.net/resources/Evidence/236982

web

fevir.net

url : https://fevir.net/resources/Evidence/236540

web

fevir.net

url : https://fevir.net/resources/Evidence/236954

web

fevir.net

url : https://fevir.net/resources/Evidence/236567

web

fevir.net

url : https://fevir.net/resources/Evidence/236987

web

fevir.net

url : https://fevir.net/resources/Evidence/236543

web

fevir.net

url : https://fevir.net/resources/Evidence/236957

web

fevir.net

url : https://fevir.net/resources/Evidence/236972

web

fevir.net

url : https://fevir.net/resources/Evidence/236552

web

fevir.net

url : https://fevir.net/resources/Evidence/236966

web

fevir.net

url : https://fevir.net/resources/Evidence/236978

web

fevir.net

url : https://fevir.net/resources/Evidence/236564

web

fevir.net

url : https://fevir.net/resources/Evidence/236984

web

fevir.net

url : https://fevir.net/resources/Evidence/236969

web

fevir.net

url : https://fevir.net/resources/Evidence/236555

web

fevir.net

url : https://fevir.net/resources/Evidence/236546

web

fevir.net

url : https://fevir.net/resources/Evidence/236960

web

fevir.net

url : https://fevir.net/resources/Evidence/236549

web

fevir.net

url : https://fevir.net/resources/Evidence/236963

web

fevir.net

url : https://fevir.net/resources/Evidence/236558

web

fevir.net

url : https://fevir.net/resources/Evidence/236975

web

fevir.net

url : https://fevir.net/resources/Evidence/236561

web

fevir.net

url : https://fevir.net/resources/Evidence/236981

web

fevir.net

url : https://fevir.net/resources/Evidence/293872

web

fevir.net

url : https://fevir.net/resources/Evidence/293980

web

fevir.net

url : https://fevir.net/resources/Evidence/293881

web

fevir.net

url : https://fevir.net/resources/Evidence/293991

web

fevir.net

url : https://fevir.net/resources/Evidence/293873

web

fevir.net

url : https://fevir.net/resources/Evidence/293981

web

fevir.net

url : https://fevir.net/resources/Evidence/293986

web

fevir.net

url : https://fevir.net/resources/Evidence/293876

web

fevir.net

url : https://fevir.net/resources/Evidence/293984

web

fevir.net

url : https://fevir.net/resources/Evidence/293988

web

fevir.net

url : https://fevir.net/resources/Evidence/293877

web

fevir.net

url : https://fevir.net/resources/Evidence/293880

web

fevir.net

url : https://fevir.net/resources/Evidence/293985

web

fevir.net

url : https://fevir.net/resources/Evidence/293990

web

fevir.net

url : https://fevir.net/resources/Evidence/293874

web

fevir.net

url : https://fevir.net/resources/Evidence/293982

web

fevir.net

url : https://fevir.net/resources/Evidence/293875

web

fevir.net

url : https://fevir.net/resources/Evidence/293983

web

fevir.net

url : https://fevir.net/resources/Evidence/293987

web

fevir.net

url : https://fevir.net/resources/Evidence/293878

web

fevir.net

url : https://fevir.net/resources/Evidence/293989

web

fevir.net

url : https://fevir.net/resources/Evidence/293879

web

fevir.net

url : https://fevir.net/resources/Evidence/367937

web

fevir.net

url : https://fevir.net/resources/Evidence/367957

web

fevir.net

url : https://fevir.net/resources/Evidence/367938

web

fevir.net

url : https://fevir.net/resources/Evidence/367940

web

fevir.net

url : https://fevir.net/resources/Evidence/367939

web

fevir.net

url : https://fevir.net/resources/Evidence/367958

web

fevir.net

url : https://fevir.net/resources/Evidence/367933

web

fevir.net

url : https://fevir.net/resources/Evidence/367934

web

fevir.net

url : https://fevir.net/resources/Evidence/367955

web

fevir.net

url : https://fevir.net/resources/Evidence/367936

web

fevir.net

url : https://fevir.net/resources/Evidence/367935

web

fevir.net

url : https://fevir.net/resources/Evidence/367956

web

fevir.net

url : https://fevir.net/resources/Evidence/367909

web

fevir.net

url : https://fevir.net/resources/Evidence/367910

web

fevir.net

url : https://fevir.net/resources/Evidence/367944

web

fevir.net

url : https://fevir.net/resources/Evidence/367906

web

fevir.net

url : https://fevir.net/resources/Evidence/367905

web

fevir.net

url : https://fevir.net/resources/Evidence/367942

web

fevir.net

url : https://fevir.net/resources/Evidence/367920

web

fevir.net

url : https://fevir.net/resources/Evidence/367919

web

fevir.net

url : https://fevir.net/resources/Evidence/367948

web

fevir.net

url : https://fevir.net/resources/Evidence/179587

web

fevir.net

url : https://fevir.net/resources/Evidence/179589

web

fevir.net

url : https://fevir.net/resources/Evidence/179588

web

fevir.net

url : https://fevir.net/resources/Evidence/179591

web

fevir.net

url : https://fevir.net/resources/Evidence/179590

web

fevir.net

url : https://fevir.net/resources/Evidence/179586

web

fevir.net

url : https://fevir.net/resources/Evidence/423311

web

fevir.net

url : https://fevir.net/resources/Evidence/367915

web

fevir.net

url : https://fevir.net/resources/Evidence/367916

web

fevir.net

url : https://fevir.net/resources/Evidence/367946

web

fevir.net

url : https://fevir.net/resources/Evidence/307455

web

fevir.net

url : https://fevir.net/resources/Evidence/312166

web

fevir.net

url : https://fevir.net/resources/Evidence/312161

web

fevir.net

url : https://fevir.net/resources/Evidence/312162

web

fevir.net

url : https://fevir.net/resources/Evidence/312165

web

fevir.net

url : https://fevir.net/resources/Evidence/312163

web

fevir.net

url : https://fevir.net/resources/Evidence/312164

web

fevir.net

url : https://fevir.net/resources/Evidence/179462

web

fevir.net

url : https://fevir.net/resources/Evidence/179464

web

fevir.net

url : https://fevir.net/resources/Evidence/179460

web

fevir.net

url : https://fevir.net/resources/Evidence/267236

web

fevir.net

url : https://fevir.net/resources/Evidence/267237

web

fevir.net

url : https://fevir.net/resources/Evidence/267244

web

fevir.net

url : https://fevir.net/resources/Evidence/267232

web

fevir.net

url : https://fevir.net/resources/Evidence/267233

web

fevir.net

url : https://fevir.net/resources/Evidence/367929

web

fevir.net

url : https://fevir.net/resources/Evidence/367953

web

fevir.net

url : https://fevir.net/resources/Evidence/367930

web

fevir.net

url : https://fevir.net/resources/Evidence/367927

web

fevir.net

url : https://fevir.net/resources/Evidence/367952

web

fevir.net

url : https://fevir.net/resources/Evidence/367928

web

fevir.net

url : https://fevir.net/resources/Evidence/267234

web

fevir.net

url : https://fevir.net/resources/Evidence/267235

web

fevir.net

url : https://fevir.net/resources/Evidence/267238

web

fevir.net

url : https://fevir.net/resources/Evidence/267239

web

fevir.net

url : https://fevir.net/resources/Evidence/267240

web

fevir.net

url : https://fevir.net/resources/Evidence/267241

web

fevir.net

url : https://fevir.net/resources/Evidence/267243

web

fevir.net

url : https://fevir.net/resources/Evidence/267242

web

fevir.net

url : https://fevir.net/resources/Evidence/367947

web

fevir.net

url : https://fevir.net/resources/Evidence/367918

web

fevir.net

url : https://fevir.net/resources/Evidence/367917

web

fevir.net

url : https://fevir.net/resources/Evidence/367913

web

fevir.net

url : https://fevir.net/resources/Evidence/367914

web

fevir.net

url : https://fevir.net/resources/Evidence/367945

web

fevir.net

url : https://fevir.net/resources/Evidence/367911

web

fevir.net

url : https://fevir.net/resources/Evidence/367912

web

fevir.net

url : https://fevir.net/resources/Evidence/307456

web

fevir.net

url : https://fevir.net/resources/Evidence/367954

web

fevir.net

url : https://fevir.net/resources/Evidence/367932

web

fevir.net

url : https://fevir.net/resources/Evidence/367931

web

fevir.net

url : https://fevir.net/resources/Evidence/307448

web

fevir.net

url : https://fevir.net/resources/Evidence/307443

web

fevir.net

url : https://fevir.net/resources/Evidence/307441

web

fevir.net

url : https://fevir.net/resources/Evidence/307253

web

fevir.net

url : https://fevir.net/resources/Evidence/307252

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/367884

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/367891

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/367882

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/423308

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/423306

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/423303

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/423305

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/423307

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/312202

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/236536

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/297490

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/236950

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/179784

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/370509

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/370508

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/367890

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/367901

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/367902

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/367899

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/367900

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/367885

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/367883

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/367889

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/367887

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/297743

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/306661

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/267228

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/267226

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/367897

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/367896

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/267227

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/267229

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/267230

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/267231

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/367888

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/370506

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/367886

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/370507

web

fevir.net

url : https://fevir.net/resources/EvidenceVariable/367898

web

fevir.net

url : https://fevir.net/resources/Group/236947

web

fevir.net

url : https://fevir.net/resources/Group/236533

web

fevir.net

url : https://fevir.net/resources/Group/236776

web

fevir.net

url : https://fevir.net/resources/Group/236530

web

fevir.net

url : https://fevir.net/resources/Group/12714

web

fevir.net

url : https://fevir.net/resources/Group/346486

web

fevir.net

url : https://fevir.net/resources/Group/372797

web

fevir.net

url : https://fevir.net/resources/Group/236948

web

fevir.net

url : https://fevir.net/resources/Group/236535

web

fevir.net

url : https://fevir.net/resources/Group/236532

web

fevir.net

url : https://fevir.net/resources/Group/236769

web

fevir.net

url : https://fevir.net/resources/Group/267225

web

fevir.net

url : https://fevir.net/resources/Group/367881

web

fevir.net

url : https://fevir.net/resources/Group/173251

web

fevir.net

url : https://fevir.net/resources/Group/7750

web

fevir.net

url : https://fevir.net/resources/Group/375175

web

fevir.net

url : https://fevir.net/resources/Group/236949

web

fevir.net

url : https://fevir.net/resources/Group/236534

web

fevir.net

url : https://fevir.net/resources/ResearchStudy/267223

web

fevir.net

url : https://fevir.net/resources/ResearchStudy/346485

web

euclinicaltrials.eu

target : https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-516402-32-00

web

tel:+33156016317

khalil.el-karoui@aphp.fr , +33156016317

web

fevir.net

url : https://fevir.net/resources/ResearchStudy/367879

web

github.com

web

creativecommons.org

https://creativecommons.org/licenses/by-nc-sa/4.0/

Show Usage

web

creativecommons.org

https://creativecommons.org/licenses/by-sa/4.0/

Show Usage

web

www.iso.org

ISO maintains the copyright on the country codes, and controls its use carefully. For further details see the ISO 3166 web page: https://www.iso.org/iso-3166-country-codes.html

Show Usage

web

www.meddra.org

Please see https://www.meddra.org/legal-mentions . For information about special licensing, see https://www.meddra.org/subscription/special-licences

Show Usage

web

www.meddra.org

https://www.meddra.org/legal-mentions

web

www.meddra.org

Please see https://www.meddra.org/legal-mentions . For information about special licensing, see https://www.meddra.org/subscription/special-licences

Show Usage

web

www.meddra.org

https://www.meddra.org/subscription/special-licences

web

creativecommons.org

SEVCO has an open license: https://creativecommons.org/licenses/by-sa/4.0/ Copyright holder is Scientific Knowledge Accelerator Foundation.

Show Usage

web

creativecommons.org

https://creativecommons.org/licenses/by-sa/4.0/

web

ucum.org

The UCUM codes, UCUM table (regardless of format), and UCUM Specification are copyright 1999-2009, Regenstrief Institute, Inc. and the Unified Codes for Units of Measures (UCUM) Organization. All rights reserved. https://ucum.org/trac/wiki/TermsOfUse

Show Usage